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As we know, 
There are known knowns. 
There are things we know we know. 
We also know 
There are known unknowns. 
That is to say 
We know there are some things 
We do not know. 
But there are also unknown unknowns, 
The one's we don't know 
We don't know. 
 
  
February 12, 2002 
Department of defense news briefing. 
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In the clinical field of anesthesia, the sciences of physiology and pharmacology 
are almost touchable. With knowledge of the mechanisms involved in the 
behavior of anesthetic agents in a continuously changing environment, the 
anesthesiologist provides the best possible conditions for the performance of 
therapeutic and diagnostic procedures while safeguarding the patient. 
 
The dose-concentration relationship of a drug, known as pharmacokinetics 
(PK), can be expressed in terms of bioavailability, absorption, distribution, 
metabolism and elimination. In anesthesia the preferred route of administration 
of a drug is intravenous, thus bypassing processes involved in the transfer of 
drug from the intestinal tract into the bloodstream. As a result, the reported 
pharmacokinetic profiles of anesthetic agents typically include the drug's 
distribution and elimination half-lives, volumes of distribution, and metabolic 
and distributional clearances. The importance of these pharmacokinetic 
parameters varies with the different phases of the anesthetic procedure. For 
example, during induction of anesthesia the initial distribution is affected by 
cardiac output and pulmonary uptake, while drug clearance may be less 
important. During maintenance of anesthesia, especially for prolonged 
procedures, drug elimination may gain clinical importance with time. 
 
The studies in this thesis focus on the pharmacokinetics and 
pharmacodynamics (PD, the concentration-effect relationship) of anesthetic 
agents during induction of anesthesia. Since the pharmacology of the induction 
of anesthesia is still poorly understood, this translates in an often troubled 
induction phase. Induction of anesthesia is associated with frequent 
underdosing causing insufficient analgesia or awareness, but also undesirable 
overdosing causing hemodynamic and respiratory depression. In general the 
pharmacology of induction of anesthesia is described using compartmental 
modeling, despite the knowledge that this methodology describes the dose-
concentration relationship at induction inaccurately.  
 
In this thesis we looked for better ways to describe the early phase PK and PD 
of agents used in anesthesia through recirculatory modeling. As indocyanine 
green plays an important role in recirculatory modeling, the first chapters deal 
with the analysis and modeling of ICG in blood. The last chapters of this thesis 
deal with the recirculatory PK and PD of rocuronium, a muscle relaxant, and 






Outline of the thesis 
 
The studies presented in this thesis were aimed at answering the following 
questions; 
 
1. Is it possible to adequately measure ICG transcutaneously for 
determination of hemodynamic parameters? 
2. Is it possible to adequately determine the plasma disappearance rate of 
ICG in a non-invasive manner and what is the range of this parameter in 
a “normal” population? 
3. Is it possible to determine a circulatory model for rocuronium in humans, 
based on intravascular and diffusion kinetics, using ICG as a marker? 
4. Can a recirculatory model based on ICG be developed for propofol in 
humans and what can be said about the role of the lung in the 
disposition and elimination of propofol? 
5. How does the implementation of a recirculatory PK model for propofol 
reflect on the ke0 of propofol and BIS in the early phase after bolus 
administration, using PK-PD modeling? 
 
In chapter 2 a review is provided on pharmacokinetic modeling of anesthetic 
drugs. Besides a general overview of the various methods of pharmacokinetic 
modeling, the recirculatory model which has been described by Kuipers et al. 
for the muscle relaxant rocuronium, using ICG as intravascular marker, is 
discussed in detail. 
 
In chapter 3 a study is presented in which the accuracy of the non-invasive 
transcutaneous measurement of ICG by the DDG-2001 is discussed. Two 
different probes were used to determine the concentration of ICG and the 
derived hemodynamic parameters cardiac output, central blood volume and 
total blood volume. These measurements were compared to the simultaneous 
measurements of ICG in arterial blood, and the derived hemodynamic 
parameters based on arterial measurements, acquired by rapid sampling. 
 
In chapter 4 the findings are presented concerning the accuracy of the non-
invasive measurement of the ICG-PDR versus arterial measurement of ICG, 
studied in the population described in chapter 3. As data on ICG-PDR 
measured transcutaneously in a population without liver failure is scarce, this 
has been explored. The implication of these findings upon clinical decision 
making in the treatment of patients, subject to imminent liver failure is 
discussed. 




In chapter 5 a circulatory pharmacokinetic model for rocuronium is presented, 
based on intravascular and diffusion kinetics. The data upon which this model 
is based were the same as used for the model described in chapter 2. The 
model applying diffusion kinetics further explores the distribution into the 
interstitial space and its relationship with cardiac output. 
 
In chapter 6 a recirculatory pharmacokinetic model for propofol in humans is 
presented. The model describes the distribution, recirculation and elimination of 
propofol, based on ICG pharmacokinetics, after the administration of an 
induction bolus dose. The role of the lung in the distribution and elimination of 
propofol is discussed. 
 
In chapter 7 the recirculatory PK model for propofol is implemented in a PK-PD 
model for propofol. Effect is measured by BIS, which is transferred at high 
frequency from the A-2000 monitor. Two different PD models are implemented 
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The science of pharmacokinetic analysis embodies the description of the time-
dependant concentration changes of a drug. Pharmacokinetic models may be 
used to predict the behavior of the drug in individuals, preferably under various 
circumstances. In the practice of anesthesia pharmacokinetics can be studied 
on the work floor. Differences in pharmacokinetics between individuals are 
observed on a daily basis. Factors responsible for the inter-individual variability 
are being studied extensively and more data become available in time. From 
these data the significance of demographic factors such as age and gender 
become increasingly apparent. Other factors like weight or lean body mass 
may substitute parameters for physiologically based variations in pathways of 
distribution and elimination. Obesity e.g. may be considered as a 
disproportionate increase of adipose tissue mass. Peripheral blood flow must 
increase to supply this extra tissue. As organ-specific blood flow remains equal, 
cardiac output will increase. The surplus of fatty tissue will act as an extra 
depot for lipid-soluble drugs like thiopental. As a consequence, peak-
concentrations are expected to decrease, whereas the terminal half-life and 
steady state volume of distribution may increase.1 Physiological parameters 
such as cardiac output, flow and tissue distribution have a more direct 
relationship with pharmacokinetic parameters like distribution volumes and 
clearances. Inclusion of a parameter like cardiac output into a pharmacokinetic 
model may improve the accuracy of the model, especially with respect to fast 
acting drugs like intravenous anesthetics. The influence of changes in cardiac 
output on the pharmacokinetics of anesthetic agents is under research. The 
largest impact of a change in the cardiac output on the behavior of drugs can 
be expected in compounds showing a flow-limited distribution and/or clearance 
such as thiopental1, lidocaine2, alfentanil3 and propofol.4 Pulmonary uptake 
may also be of influence on the early-phase distribution of a substance. These 
influences will be described in more detail further on in this chapter. 
 
Another factor of influence on drug behavior is the method of administration. A 
rapid intravenous bolus injection will be best characterized by a set of 
pharmacokinetic parameters different from parameters derived after a 
prolonged intravenous infusion, as is used in devices for target controlled 
infusion (TCI).5,6 Prolonged infusion of a drug with a rapid clearance and 
extensive distribution, such as propofol, may be better characterized by a        
3-compartment model, whereas for a bolus injection a 2-compartment model 
may suffice. In a study published by Schnider and colleagues, is shown that 





by the pharmacokinetics derived from blood samples taken during a propofol 
infusion in the same patients.7 The drug concentrations during the first 
10 minutes after a bolus injection were significantly biased with an 
overestimation at minute 2 and 4 followed by a subsequent underestimation of 
the actual propofol concentration. Selecting the right pharmacokinetic model for 
the right type of administration and phase of interest (early-phase or steady-
state) is important. 
 
 
Selecting a pharmacokinetic model 
 
A large variety of pharmacokinetic models exists ranging from very abstract    
to naturalistic.8 The commonly used models are linear and time-invariant 
(Figure 1). Empirical models describe the relationship between input, the drug 
dose, and output, the plasma concentration, in a mathematical form without 
reference to a physiological or pharmacological explanation. Empirical models 
treat the human body as a black box. The key to this method is the fitting 
procedure. Compartmental models are most frequently applied, consisting of  
2- or 3-compartments. These compartments may have a physiological (plasma, 
tissue) basis but are derived purely mathematically. 
 
 
Figure 1 A taxonomy of pharmacokinetic models. Reproduced from J. Kuipers, 




Compartmental models are based on the assumption of instantaneous mixing 
of the drug after a bolus injection within the central compartment. Distribution 
and elimination occur solely from the central compartment. Other 




compartments serve as “peripheral” compartments, with “slow” equilibration 
constants, from which the drug is redistributed. By assuming complete initial 
mixing within the central compartment, which is actually not the case, the 
compartmental model becomes inaccurate when pulmonary uptake or the 
process of initial mixing in the first minutes after injection are studied. 
 
 
The development of recirculatory models 
 
In the process of the pharmacokinetic evaluation of concentration-time data, 
analysis is frequently performed by fitting data to a 2- or 3-compartment model. 
However, for some anesthetic agents this may not be the best model suited. 
More and more drugs are introduced that exhibit a very rapid initial distribution, 
resulting in the propagation of a clinical effect before complete mixing has 
occurred. Ignoring the mechanism of initial mixing may lead to significant 
deviations in the estimation of the volume of the central compartment.9 Other 
drugs such as fentanyl, meperidine10, sufentanil11, propofol12,13, ketamine14 and 
lidocaine15,16 are known to undergo substantial pulmonary uptake. Furthermore, 
in fast acting compounds the distribution appears to be flow dependant.17 
Including a flow parameter such as cardiac output into the model is therefore 
strongly desired.1 Taking these factors into consideration, one may suggest 
that the examination of early phase pharmacokinetics based exclusively on 
conventional compartment modeling, may be insufficient18 and provide 
inaccurate data. 
 
One solution to the issues mentioned is the system dynamics approach as 
described by van Rossum.19 This approach provides a different method of 
modeling by calculation of so-called body transfer functions. The transport 
function of the body (closed loop) is considered a stochastic process 
characterized by a density function of total body residence times. The 
relationship between the body transit time distribution and the body residence 
distribution is determined by the feedback-loop arrangement, the cardiac output 
and the extraction ratio. The cardiac output is included as an important 
hemodynamic variable in this model.20 
 
Other models allowing recirculation have been introduced, constructed as 
catenary compartmental models with different compartments linked in a serial 
manner. In a study by Avram and colleagues, this model of concurrent 
disposition of ICG and thiopental allowed to analyze intravascular mixing by 





peripheral compartment for thiopental.21 Further development led to 
recirculatory models using ICG as a marker for the intravascular 
compartment.22 Finally, a combination of recirculatory compartments and 
peripheral slow and fast tissue compartments was developed that made the 
recirculatory model more physiologically based.23 
 
For any drug the complete recirculatory model can be built on the basis of a 
model for ICG. Since the distribution of ICG is limited to the intravascular 
space, the ICG model describes the passage through the central and 
peripheral blood compartments. The central compartments are by definition 
located between the venous point of injection and the arterial point of sampling. 
The central intravascular part of the model, representing the flow through the 
heart and lungs, is best described by two compartments. Hereby, modeling of 
pulmonary uptake and redistribution is allowed. Since the mean transit time of 
one compartment is shorter that that of the other compartment, they are 
identified as the fast central and the slow central compartment. Peripheral 
compartments are described similarly. The compartments for ICG are 
considered to represent the effect of dispersion of ICG in the vascular tree. In 
the model this dispersion is simulated by so-called tanks-in-series, being very 
small consecutive compartments from which the drug is cleared exponentially. 
Parallel pathways can differ in the number of tanks in series and the proportion 
of the blood flow to the respective compartments. 
 
For the test drug peripheral tissue compartments are added to the ICG model. 
These tissue compartments are similar to the compartments of other catenary 
models. The tissue compartments are coupled to the peripheral vascular 
compartments such that the slow vascular compartment is coupled to the slow 
tissue compartment. If the drug undergoes significant pulmonary uptake a 
pulmonary tissue compartment may be added21 (see figure 2). 
 
 
Recirculatory modeling in practice 
 
Recirculatory models for different compounds such as thiopental21, halothane24, 
alfentanil3,25, propofol12, and rocuronium26 have been described. As a marker 
for the intravascular compartment ICG was used. To adequately measure the 
recirculation of ICG the sampling frequency must be high; the process of initial 
mixing is complete within 5 minutes. The quality of model fitting is therefore 
highly dependent on the amount of blood samples taken within the first minutes 
after the bolus dose administration. From these samples the first-pass 




concentration curve of ICG can be determined, described by two parallel 
pathways consisting of Erlang functions, represented by a number of tanks in 




Figure 2. Recirculatory pharmacokinetic model used for analysis of indocyanine green 
and simultaneously injected drug (modified from Krejcie et al.23). The parts in the 
dashed boxes represent the recirculatory model for indocyanine green, the 
intravascular part of the model. These intravascular compartments are represented by 
a rectangle with five compartments, but the actual number of compartments may vary 
and has no physiological background. The intravascular model consists of a central 
part, receiving all of the cardiac output, divided in a slow (VC_s) and a fast (VC_f) central 
compartment and a peripheral part, divided in a slow (VND_s) and a fast (VND_s) 
peripheral compartment. The simultaneously injected drug distributes into organs and 
therefore, 3 tissue compartments are added to the intravascular indocyanine green 
model; the lung compartment (Vlung), a slow (VT_s) and a fast (VT_f) peripheral tissue 
compartment. The sum of the peripheral clearances equals the cardiac output. 
Reproduced from J. Kuipers, Pharmacokinetic modelling of anaesthetics; The role of 






The parameters derived from this model can now be combined with peripheral 
compartments to represent distribution and elimination as described above. 
Constructing such a model is possible using the SAAM II program (SAAM 
institute, University of Washington, Seattle, USA). It consists of a numerical 
mode and compartmental mode. The latter allows for the construction of a 
model on a canvas where the program attaches the formulas. The solver 
function of the program computes the parameters in an iterative way with fixed 
or relative weights (SAAM II manual). The statistics performed on the 
parameters are calculation of the standard deviation, fractional standard 
deviation and representation of a correlation matrix, covariance matrix or the 
residual sum of squares, including the Akaike criterion. Other statistical tests 
described are the one sample runs test to check for random scatter around the 
fit. The group of Krejcie uses the IDENT2 program to check for identifiability 





As an example of differences in pharmacokinetic outcome using conventional 
2-compartment modeling compared to recirculatory modeling, a short 
representation will be given of the results from a study performed by Kuipers 
and colleagues regarding the pharmacokinetics of rocuronium in patients.26 In 
this study a recirculatory model has been used based on arterial ICG 
concentrations collected with a rapid sampling device. In addition, cardiac 
output was determined by dividing the dose of ICG by the area under the first-
pass ICG concentration-time curve. Rocuronium had been selected as a model 
drug because of its fast onset of action. The effect of rocuronium could be 
quantified easily and reliably and be expected to be linked to cardiac output 
based on its dependency on the blood flow through the muscles. In addition, 
the effect measurements were included in a PK-PD model to determine the   
ke0 of rocuronium using compartmental modeling parameters and recirculatory 
modeling parameters. The recirculatory model, used to analyze indocyanine 
green and rocuronium pharmacokinetics and the rocuronium pharmaco-
dynamics, was built like the model in figure 2, with the exclusion of the lung 
compartment and with the addition of an effect compartment placed after the 
arterial sampling site. The effect compartment was not included in the 
recirculatory system. The sum of the clearances through the parallel fast and 
slow non-distributive circuits for ICG equals the cardiac output. Rocuronium 
data were evaluated by addition of a fast and slow peripheral distributive 
compartment to the ICG model. The ratio between fast and slow peripheral 




clearances was set equal for ICG and rocuronium, but the absolute values 
were allowed to differ. The pharmacokinetic data could well be fitted using 
recirculatory pharmacokinetics, whereas the two-compartment model showed 
large uncertainty regarding the drug behavior in the first minutes. A 
pharmacokinetic-pharmacodynamic analysis could be done using recirculatory 
pharmacokinetics as well. Some of the parameters determined by the 
recirculatory model and the two-compartment model can be seen in table 1. 
 
 
Table 1 Pharmacokinetic and pharmacokinetic-dynamic parameters of rocuronium 
determined by a recirculatory model and 2-compartment model (mean and SD). For 
abbreviations see legend of figure 2. The unit of ke0 is (min
-1), of EC50 is (µg.L
-1) 
 
 VC Vss VT ClEL V1 V2 Cl12 Ke0 EC50 
Recirculatory          
Mean 1.52 17.29 14.77 0.45    0.129 876 
SD 0.40 4.82 4.85 0.11    0.036 118 
2-compartment          
Mean  10.50  0.50 6.76 3.73 0.43 0.239 684 
SD  3.54  0.14 1.69 1.98 0.20 0.104 97 
 
Reproduced from J. Kuipers, Pharmacokinetic modelling of anaesthetics: the role of cardiac output. 
PhD thesis, with permission. 
 
 
The results showed correlation between cardiac output and the central volume 
of ICG and rocuronium. The clearances correlated significantly with cardiac 
output as well. The values of ke0 and EC50 obtained with the compartmental 
model were significantly different from the values estimated with the 
recirculatory model. The ke0 determined using the compartmental model was 
nearly double and the EC50 approximately 22% lower compared to those 
determined on the basis of the recirculatory approach. The ke0 of rocuronium 
showed correlation with cardiac output, although the correlation estimated from 
the recirculatory model was much stronger. This could well be explained by the 
difference in accuracy of fitting in the first minutes. It is known that by selecting 
a model, i.e. a 2- or 3-compartment model, the initial drug concentration may 
be either seriously underestimated or overestimated. In contrast, the 
recirculatory model was capable of accurately describing the front-end 
kinetics.28 The correlation between cardiac output and effect site-equilibration 





output (2.4 L.min-1) showed 90% twitch depression after 2.5 minutes, whereas 
the patient with the highest cardiac output (5.0 L.min-1) needed only 
1.5 minutes for near-complete relaxation. In the context of a rapid sequence 
induction, this means that not only the dose of muscle relaxant, but also the 
physiological status of the patient needs consideration. This supports the need 
for more accurate characterization of pharmacokinetic and pharmacodynamic 





With the introduction of an increasing number of compounds exhibiting a rapid, 
flow dependant distribution and a rapid onset of effect before complete mixing, 
it becomes increasingly important to look at alternatives in pharmacokinetic 
modeling. At present, the most frequently used approach is the conventional   
2- or 3- compartment model. This model is based on the assumption of 
complete mixing in the central compartment upon bolus-injection of the 
compound. In this model recirculation, flow-dependant distribution or pulmonary 
uptake are not taken into account. The introduction of recirculatory modeling as 
described by Krejcie et al.23 provides a tool to model data in these situations. 
Disadvantages of recirculatory modeling are innate to the small time frame in 
which the processes take place. First of all, it is necessary to administer a 
marker for the intravascular space (ICG) in combination with the compound of 
interest. Secondly, in order to have sufficient data to model the first-pass 
circulation of ICG, the sampling frequency must be high; every few seconds. 
Besides the practical implications of this methodology, it implies that the quality 
of the fit is highly dependant on the number of data points within the first 
3 minutes. Accurate modeling of early-phase pharmacokinetics is very 
important, since the better the understanding of the behavior of a drug in a 
“standard” situation (read “healthy subject”), the easier to predict the outcome 
when parameters change. Extending the knowledge in this field may lead to a 
better prediction of drug behavior in e.g. elderly patients or in patients with an 
altered cardiovascular state. The development of techniques to measure 
cardiac output in a non- or minimal invasive way, preferably on a beat-to-beat 
basis, may lead to fine-tuning of the pharmacokinetics of intravenous 
anesthetics on a patient-basis. In addition, it has also been shown that 
recirculatory modeling can be used in pharmacokinetic-pharmacodynamic 
modeling. This may lead to differences in the estimation of ke0 and EC50 
compared to conventional approaches, as has been shown in the paragraph 
above. 




In conclusion, recirculatory modeling may produce a more accurate prediction 
of actual blood and tissue drug concentrations, especially for rapid acting 
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Noninvasive cardiac output (CO) monitoring has gained increasing clinical 
attention in recent years. Various methods have been developed, based on 
different techniques, with variation in reliability and clinical applicability. Pulse 
Dye Densitometry (PDD) uses the indicator dilution technique and requires only 
intravenous access. The indicator Indocyanine Green (ICG) is confined to the 
intravascular space due to its hydrophilic character and binding to plasma 
proteins and is cleared from the blood through the liver.1 ICG has been used 
frequently to determine cardiovascular parameters such as cardiac output2,3, 
cardiac index, blood volume4-8, liver blood flow9-11, and lung-uptake of drug 
components like lidocaine12 through dye dilution. With the introduction of PDD, 
an adaptation of pulse spectrophotometry, it became possible to measure ICG 
noninvasively by means of transcutaneous spectrophotometry using a finger or 
nose probe.13 
 
Three validation studies of the measurement of the arterial blood ICG 
concentration versus pulse dye densitometry have been published so far.13-15 In 
these studies, blood samples were taken after recirculation had taken place. 
However, the phase of initial mixing, before recirculation of the dye, is the 
period in which the data are gathered for the estimation of cardiac output and 
central blood volume (CBV), since the area under the first pass curve is needed 
for the calculation of these parameters. In the study published by Sakka and 
colleagues, intravascular measurement of ICG using a fiberoptic device 
showed good agreement with transcutaneous measurement of ICG for the 
determination of total blood volume (TBV), moderately for CBV and could not 
be performed for CO, due to inaccurate detection of the first-pass curve.16 
Consequently, validation of transcutaneous measurement of ICG by PDD 
versus ICG concentration measurements in arterial blood during the initial 
mixing phase is not available. 
 
To evaluate the noninvasive measurement of ICG using pulse dye 
densitometry, we compared in a group of patients the ICG data measured 
using the PDD finger or nose probe to the ICG concentrations in arterial   











Study design and subjects 
The ICG concentrations determined noninvasively by PDD and invasively in 
arterial blood were taken from patients who participated in either of two yet 
unpublished pharmacological studies. In 10 patients ICG concentrations were 
measured using the PDD finger probe, in 10 other patients the nose probe was 
used. The studies were performed after obtaining approval from the Medical 
Ethics Committee of the Leiden University Medical Centre and the patients’ 
written informed consent. The patients were ASA physical status I or II and 
participated in the study prior to elective surgery. Exclusion criteria included a 
medical history of severe cardiovascular, respiratory, renal, hepatic, 
neurological or psychiatric disease, use of anti-hypertensive or anti-arrhythmic 
medication, pregnancy or lactation, and a history of hypersensitivity to amide 
local anesthetics or ICG. 
 
Prior to the measurements a large venous cannula was inserted in the fossa 
cubiti and the radial artery was cannulated for gathering blood samples with a 
22 G cannula. Placement of the finger probe was on the index finger and the 
nose probe on the right nasal wing. Cooling of the extremities was prevented to 
maintain signal quality. An experimental session only started when the PDD 
indicated a sufficient signal quality as measured by the finger or nose probe. 
Sufficient was judged a minimum of two out of five units as indicated on the 
DDG-2001. Each session started with the intravenous administration of 10 mg 
ICG (Infracyanine®), followed by a rapid bolus of 20 ml of saline. A computer-
controlled syringe pump with fraction collector drew arterial blood samples at 
3 sec intervals for the first min, and at 10 sec intervals for the second minute. 
Eight more samples were drawn manually up to 15 min after administration of 
the ICG bolus dose. The sampling system consists of a disposable sampling 
set, an automatic sampler and a carrousel with test tubes. The automatic 
sampler is a custom made device that can move a syringe plunger to a set 
volume and moves a stopcock in coordination with sampling. The sampler is 
connected to a computer that times the sampling. Because of limitations in 
blood flow in the radial artery the sampling rate is maximally 1 per 3 sec. The 
carrousel moves synchronous to the sampling. The disposable sampling 
system consists of a syringe with a stopcock, extension tubing between the 
patient and the sampling syringe, and extension tubing to the test tubes 
mounted on the carrousel.  The extension tubing to the patient is connected 
with a stopcock to the intra-arterial catheter. The volumes in the extension 
tubes with the stopcocks have a dead space volume of 1.8 ml. The sampling 




volume was set to 1.8 ml and is thus identical to the dead space in the 
extension tubes. Each sampling cycle consisted of drawing the sample from the 
patient, turning the stopcock on the syringe and then ejecting the content of the 
syringe to the extension tube to the test tubes. Since the movement of blood in 
the system is fully controlled, mixing of samples in the tubing is unlikely and 
each sample represents the concentration at the sampling time. The blood 
samples were collected in heparinized glass tubes and processed immediately. 
 
The patients in whom the finger probe was used for determination of ICG 
concentrations underwent up to 3 repeated measurements in the same session 
separated by a time period of at least 15 min to allow for dye excretion. During 
each measurement patients were awake and in a hemodynamically stable 
condition. In the patients in whom the nose probe was used for the 
determination of ICG concentrations, single measurements were performed, as 
patients were studied during induction of anesthesia. 
 
Measurements of ICG in blood  
The concentrations of ICG were determined in whole blood using High 
Performance Liquid Chromatography (HPLC) (Separations analytical 
instruments, Hendrik-Ido-Ambacht, The Netherlands; column: Ultrasphere ODS 
4.6 x 7.5 cm 244254, Beckman Coulter, Mijdrecht, The Netherlands) with 
ultraviolet and fluorescence detection. For each patient a calibration curve was 
constructed, using the patients own blood prior to injection of ICG. The 
fluorescence settings were as follows; excitation at a wavelength of 780 nm 
and the emission wavelength at 810 nm with a gain of 100. ICG was also 
measured at 777 nm, its peak in the spectrum. Both ICG and its degradation 
product were identified by a diode array (Photodiodedetector PDA 100, Dionex, 
Amsterdam, The Netherlands). The detection limit of the whole blood assay for 
ICG was at 0.15 or 0.2 mg.L-1. The coefficient of variation was less than 6 % 
over the range from 0.5 to 10.45 mg.L-1. 
 
Data collection and processing 
Pulse Dye Densitometry was performed using the DDG-2001 A/K (Nihon 
Kohden, Tokyo, Japan). Data were transferred to a laptop-computer and 
imported into a spreadsheet program (Excel 2000, Microsoft Corporation, 
Seattle, U.S.A.). Arterial blood concentrations were imported in the same 
spreadsheet program to undergo further analysis. 
 
Cardiac output was calculated by dividing the administered ICG dose by the 





shape of the first pass concentration-time curve, including all data before 
evidence of ICG recirculation, was log-linearly described by the sum of two 
Erlang functions, each representing the convolution of n 1-compartment models 



























where n1 and n2 are the number of compartments in series in the central delay 
elements; k1 and k2 are the rate constants between the compartments in series; 
n1/k1 and n2/k2 are the mean transit times (MTT) of the central delay elements; 
A1 and A2 are the areas under the first pass concentration time curves. The two 
Erlang functions were fitted to the data using the solver function in Excel 
(Microsoft Corporation, Seattle, U.S.A.), whereby data were uniformly 
weighted. 
 
Total blood volume was estimated as TBV=D/C0, in which D is the dose 
administered and C0 is the log-linearly back-extrapolated concentration at 
mean transit time, when first mixing but no elimination of ICG has occurred 
during the first circulation. The intrathoracic or central blood volume is 
determined as the product of CO and MTT.  
 
Statistical analysis 
Comparison of the two methods in both groups (nose and finger probe) was 
done by Bland-Altman analysis18, reporting mean difference (bias) and Limits of 
Agreement (LOA, bias ± 2 SD). In the group using the finger probe, the total 
variance due to intra- and interindividual differences has been taken into 
account using additional oneway analysis of variance.19 Comparison of ICG 
peak concentrations using the finger or nose probe versus the arterial blood 






Patient characteristics of both groups are represented in table 1. 
 
 




Table 1 Patient characteristics (data presented as median and range). 
 
 Finger probe group Nose probe group 
Patients (n) 10 10 
Sessions (n) 26 10 
Gender (M/F) 4 / 6  2 / 8  
Age (yr) 56 (21-86) 44.5 (23-53) 
Weight (kg) 67 (63-92) 65.5 (55-95) 
Height (m) 1.70 (1.56-1.87) 1.71 (1.58-1.97) 




ICG concentration curves 
In both sets of patients, it regularly proved difficult to obtain an adequate signal 
quality. 
 
In two sessions performed with the finger probe the generated ICG curves 
consisted of a small-based concentration peak, generating CBV of 22.7 and 
26.8 L and an accordingly high CO of 35 and 47.3 L.min-1. Since these figures 
were far beyond physiologically acceptable values, the results for CO and CBV 
were excluded from the Bland-Altman analysis. 
 
Due to the rapid arterial blood sampling it was possible to obtain an adequate 
number of data points to define the peak in the arterial ICG concentration, 
including recirculation of the dye. In each experiment, on average, 32 arterial 
blood samples for blood ICG concentration determination were taken, of which 
20 were in the first minute. In both groups, the peak blood ICG concentration 
measured by PDD was generally higher than in the arterial blood. The average 
difference of +29%  36% (mean ± SD) using the finger probe (n=24, p<0.001) 
and +34.2%  46.5% (mean ± SD) using the nose probe (n=9, p=0.079). 
Furthermore, the peak concentration of ICG measured by PDD lagged behind 
the arterial blood ICG peak concentration. The average time shift between the 
noninvasively and invasively measured ICG concentration was 9.6 sec  9 (SD) 
in the finger probe group. In the nose probe group this time shift did not occur. 
Examples of ICG concentration curves showing a marked difference in MTT 
between invasive and noninvasive ICG measurements using the finger probe 





successive sessions. In this case no clear differences in peak concentrations 
were observed. 
 
Figure 1 Indocyanine Green (ICG) concentration-time data of 3 sessions in a single 
patient, determined by the pulse dye densitometry (PDD) finger probe (open markers) 
and from arterial blood (closed markers). Note the time shift in the first experiment 
(panel A) and the difference in first circulation in the third experiment (panel C). 




Hemodynamic parameters using the finger probe 
In 24 datasets the cardiac output (CO) and central blood volume (CBV) and in 
26 datasets total blood volume (TBV) were calculated and compared. TBV was 
recalculated from the raw data, using a spreadsheet with the algorithms as 
described in the methods section, to correct for major noise artifacts by 
adjusting the interval of the curve used for back-extrapolation to C0. The Bland-
Altman analysis revealed a mean absolute difference and limits of agreement 
between PDD and invasive measurements for CO of -0.43 L.min-1  (-4.76 and 
3.90 L.min-1); for CBV of 0.76 L (-2.45 and 3.97 L) and for TBV of -1.42 L (-3.88 
and 1.03 L) (Figure 2). The Bland-Altman analysis revealed a mean relative 
difference and LOA between PDD and invasive measurements for CO of -5%  
(-56% and 47%); for CBV of 21% (-54% and 96%) and for TBV of -15% (-38% 
and 8%). 
 
Hemodynamic parameters using the nose probe 
In all data sets (n = 10) the CO, central blood volume (CBV) and total blood 
volume (TBV) were compared. The Bland-Altman analysis revealed an 
absolute bias and LOA between PDD and invasive measurements for CO of 
2.26 L.min-1 (-4.67 and 9.20 L.min-1); for CBV of 0.79 L (-2.08 and 3.66 L) and 
for TBV of -0.73 L (-3.48 and 2.01 L) (Figure 3). The Bland-Altman analysis 
revealed a mean relative difference and LOA between PDD and invasive 
measurements for CO of 30% (-67% and 127%); for CBV of 48% (-98% and 





Various studies on the comparison of PDD derived cardiovascular parameters 
versus intravascular measurements by e.g. a pulmonary artery catheter have 
been published: on cardiac output (CO)3,20-23, central (or intrathoracic) blood 
volume (CBV)4, total blood volume (TBV)13, and hepatic blood flow.24 The 
noninvasively derived dye dilution curve was not validated in any of these 
publications, yet the derived parameters were compared to results obtained by 
other methods of measurement. In other words, no study so far accurately 
compared frequently gathered arterial ICG concentrations before complete 
mixing had occurred with the noninvasive ICG data by PDD and evaluated the 
derived cardiovascular parameters based on these invasive and noninvasive 








Figure 2 The bias (PDD-arterial) and limits of agreement (± 2 SD) for cardiac output 
(A), central blood volume (B) and total blood volume (C), measured by the pulse dye 
densitometry (PDD) finger probe. 






Figure 3 The bias (PDD-arterial) and limits of agreement (± 2 SD) for cardiac output 
(A), central blood volume (B) and total blood volume (C), measured by the pulse dye 





In this study we evaluated the hemodynamic parameters based on noninvasive 
ICG measurements by pulse dye densitometry, using a finger or nose probe, 
and compared them to those based on invasive ICG measurements in the 
arterial blood. 
 
Arterial measurement of ICG concentrations is not considered to be the gold 
standard for the determination of cardiovascular parameters. On the other 
hand, comparison of these two methods is the most accurate way to evaluate 
the underlying technique used in PDD. Hence, Bland-Altman analysis of the 
results is the only allowed method for comparison of the results. The data in the 
first part of this study were gathered using the finger probe; initially this probe 
was chosen because the anatomical proximity of the two sample sites (the 
radial artery and the index finger) was likely to improve the comparability of the 
data. To improve the comparison, we included a second patient group using 
the nose probe. For determination of TBV and the ICG plasma disappearance 
rate (ICG-PDR), both probes generally are considered equally reliable.5,6,14 
Some studies, however, suggest that the nose probe may be more reliable for 
determination of cardiac output21, whereas other studies do not favor either 
probe for CO determination.13,15 Our results show an overestimation of CO by 
the nose-probe and underestimation by the finger probe. Providing physio-
pathological support for this finding is difficult. One can speculate that the 
influence of vasoconstriction in the microvasculature, tissue volume at the 
probe site and the proportion of mixed tissue absorption in the digits is more 
elaborate then in the nasal wing. 
 
We conclude that transcutaneous measurements by PDD result in higher 
(finger and nose probe) and postponed (finger probe) ICG concentrations 
compared to arterial ICG concentration measurements of the same bolus of 
ICG. Any difference in detection of ICG peak concentration has influence on 
both CO and CBV calculation, as it affects the AUC. The phase shift is of 
consequence in the calculation of CBV, since it directly affects the MTT. 
Therefore, the PDD-derived hemodynamic parameters cardiac output and 
central blood volumes are inaccurate. As a consequence of the wide limits of 
agreement, in an individual patient with a CO of 6 L.min-1, PDD could measure 
a CO of 3 L.min-1 or 9 L.min-1. This huge uncertainty significantly limits the use 
of PDD for the monitoring of CO in the individual patient. 
 
The measurements of total blood volume correlated better. This can be 
explained by the fact that TBV is less influenced by a time shift in the first 
circulation curve, as long as the elimination curve compares well between the 
two methods. Before accepting a PDD generated TBV value, we recommend 




taking the complete concentration curve into consideration: when (motion) 
artifacts occur in the interval used for back-extrapolation, estimation of the 
down slope may be highly affected and manual adjustment of the interval is 
necessary. 
 
The clinical conditions, under which the two probes were tested, varied 
between subjects in the two studies. At higher ranges of the parameters 
determined, the relative differences between the methods did not show an 
increase. The magnitude of the bias is therefore not related to the range of 
cardiac output or TBV in our study. 
 
Study limitations 
Ideally, the comparison of the two probes would have been performed in a 
randomized cross-over manner, but due to the separate protocols and pre-
operative character of the experiments, this was not possible. Unfortunately it 
was not possible to use both probes simultaneously. 
 
Underestimation of the peak ICG concentration by arterial sampling may in part 
be explained by the lower sample frequency. However, even when smoothing 
of the curve by a moving average is assumed, the influence on the AUC should 
be minimal. Furthermore, the gathering of 6-8 arterial blood samples during   
the first circulation of ICG (usually 12-20 sec) is the maximum achievable in 
practice. Variability in the ICG measurements in blood was low; in some cases 
however, it was more difficult to fit the first circulation. This could occur in 
patients with a high cardiac output, generating less data points in the first 
circulation of the dye. 
 
In our study two sessions performed with the finger probe were excluded in the 
Bland-Altman analysis for CO and CBV. The detected PDD concentration 
curves showed a small based peak during the first circulation, generating a 
very small AUC. The results for CO and CBV were over 20 L (per min) and 
clearly wrong. Incorrect detection of the PDD may lie in the signal:noise ratio 
being influenced by motion or low pulsatility of the signal due to constriction of 
the microvasculature in the digit. The signal may even be merely a reflection of 
a mixed tissue level, due to the passage of the indicator through small 
arterioles, capillaries and small veins. There was however no obvious reason 
for the findings in these sessions. Bremer et al. report an average of 5 
performed measurements by PDD to collect 3 apparently valid recordings20, 
Haruna and colleagues excluded 3 out of 10 volunteers due to motion artifacts 





the concentration peak is not smooth, the PDD device may generate an 
inadequate fit of the first circulation. This cannot be adjusted manually.  
 
We recommend the (future) user of the PDD method to pay attention to the 
following aspects: optimize signal quality by guarding the temperature of the 
probe site, avoid vasoconstriction, avoid excess light at the probe site, avoid 
motion of the patient or probe, check the signal quality during the measurement 
(aim for a minimum of 2 out of 5 units on the display), observe the concen-
tration curve for adequacy of fit of the first circulation, adjust the interval for 
back-extrapolation if necessary. 
 
Conclusion 
In conclusion, the results of this study significantly question the reliability of 
pulse dye densitometry by Nihon Kohden for cardiac output and central blood 
volume measurement in the individual patient. The nose and finger probe were 
equally unreliable. Given the wide limits of agreement, pulse dye densitometry 
could misinform the clinician about the actual hemodynamic status of the 
patient. Despite the need for less invasive methods of cardiac output 
measurement, better alternatives than PDD are required. PDD is better suitable 
for measurement of total blood volume, as our findings indicate. PDD is used 
also as an indicator for hepatic clearance and hepatic blood flow, especially 
during liver transplantation.24-26 The application of PDD for this purpose 
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Indocyanine Green dye (ICG) is extracted from the blood by hepatic 
parenchymal cells without undergoing enterohepatic circulation.1 The hepatic 
clearance of ICG is used for the assessment of hepatic (residual) function.2-5 
The elimination of ICG can be reported as ICG plasma disappearance rate 
(ICG-PDR), which is the decline in the log-linear elimination curve after the iv 
administration of a bolus of ICG, expressed as percentage per min. Various 
reports have been published on the measurement of ICG-PDR for the 
monitoring of hepatic function during anesthesia and after liver 
transplantation.6-9 In addition, ICG-PDR is reported as a prognostic factor in the 
critically ill.10-13 
 
With Pulse Dye Densitometry (PDD), an adaptation of pulse 
spectrophotometry, it is now possible to measure ICG non-invasively by means 
of transcutaneous pulse spectrophotometry using a finger or nose probe. 
Transcutaneously measured ICG concentrations have been shown to correlate 
very closely to arterial blood ICG concentration measurements in man14,15 and 
in a porcine model.16 
 
Although the measurement of ICG has been validated properly, the actual 
mean value and range of ICG disappearance in the healthy population and the 
cutoff value that discriminates between a normal and impaired hepatic function 
has not yet been described clearly. Often one refers to a single publication, 
which is a book chapter that is not readily available.17 Other publications on the 
subject date from almost 50 years back and are determined by invasive blood 
sampling. Nonetheless, information on the range and variability of ICG-PDR in 
healthy persons is prudent for the interpretation of single or repeated ICG 
disappearance measurements in the evaluation of liver graft function, hepatic 
blood flow, or assessment of liver failure in septic shock. 
 
To increase the knowledge of ICG disappearance in a healthy population we 
evaluated the ICG disappearance rate (ICG-PDR values) in ASA physical 
status I-II patients not known with hepatic or cardiovascular disease. 
Measurement of ICG-PDR was performed transcutaneously by Pulse Dye 
Densitometry using either a finger probe or nose probe. In addition, we 
compared the transcutaneous measurement of ICG-PDR using PDD to 










For the determination of the ICG plasma disappearance in an otherwise healthy 
surgical population, 41 patients were evaluated as they participated in one of 
two sequential pharmacological studies. In 33 patients, involved in a study on 
the cardiovascular effects of lumbar epidural anaesthesia with ropivacaine 
0.75%, ICG concentrations were measured using the PDD finger probe. 
Measurements were performed before introduction of epidural anaesthesia. In 
8 other patients, involved in a study on pharmacokinetic-pharmacodynamic 
modeling of propofol, ICG concentrations were measured using the PDD nose 
probe. To compare transcutaneous measurement of ICG-PDR with invasive 
measurements, multiple simultaneous ICG measurements in arterial blood 
were collected in a subset of 10 patients from the first group and all 8 patients 
from the second group. The studies were performed after obtaining approval 
from the Medical Ethics Committee of the Leiden University Medical Centre and 
the patients’ written informed consent. The patients were ASA physical status 
I or II scheduled for elective surgery. Exclusion criteria included a medical 
history of severe cardiovascular, respiratory, renal, hepatic, neurological or 
psychiatric disease, use of anti-hypertensive or anti-arrhythmic medication, 
pregnancy or lactation and a history of hypersensitivity to amide local 
anesthetics or indocyanine green. In 9 of the 41 patients (22%) chemical 
testing of liver function had been performed previously by our hospital 
laboratory and the results were within normal limits. 
 
Procedures 
Prior to the ICG clearance measurements a cannula was inserted in a large 
vein in the fossa cubiti. In 18 patients the radial artery was also cannulated for 
the collection of arterial blood samples. Pulse Dye Densitometry was performed 
using the DDG-2001 A/K (Nihon Kohden, Tokyo, Japan). Each session started 
with the intravenous administration of 10 mg ICG (Infracyanine®), followed by a 
rapid bolus of 20 ml of saline. In the group of patients in whom arterial blood 
samples were taken, a computer-controlled syringe pump was programmed to 
draw up to 33 arterial blood samples of 1.5 ml in the first 2 min after ICG 
administration. Starting from the second minute a waste sample was drawn 
first, to avoid mixing within the sampling line. The blood samples were collected 
in heparinized glass tubes and processed immediately. In the finger probe 
group, arterial sampling continued up to 15 min following ICG bolus 
administration. In the nose probe group, arterial blood sampling continued       




6-10 min after bolus administration, depending on the return of consciousness, 
when measurements were terminated. Once complete mixing of the dye was 
observed, a median number of 7 arterial ICG concentration data points were 
available for fitting the log-linear elimination curve. 
 
Measurements of ICG in blood  
The concentrations of ICG were determined in whole blood using High 
Performance Liquid Chromatography (Separations analytical instruments, 
Hendrik-Ido-Ambacht, The Netherlands; column: Ultrasphere ODS 4.6 x 7.5 cm 
244254, Beckman Coulter, Mijdrecht, The Netherlands) with ultraviolet and 
fluorescence detection. The fluorescence settings were as follows: excitation at 
a wavelength of 780 nm and emission wavelength at 810 nm with a gain of 
100. ICG was also measured at 777 nm, its peak in the spectrum. Both ICG 
and its degradation product were identified by a diode array 
(Photodiodedetector PDA 100, Dionex, Amsterdam, The Netherlands). The 
detection limit of the whole blood assay for ICG was at 0.15 or 0.2 mg.L-1.     
The coefficient of variation was less than 6 % over the range from 0.5 to 
10.45 mg.L-1. 
 
Data collection and processing 
ICG-blood concentration data as determined by PDD and from the arterial 
blood were imported in a spreadsheet program (Excel 2000, Microsoft 
Corporation, Seattle, U.S.A.). KICG, the rate constant characterizing the ICG 
decay curve, was calculated by fitting a semi logarithmic regression curve 
through the declining part of the ICG concentration curve in the interval of       
2-5 min after administration of the bolus ICG. The concentration curve is a 
monoexponential decay curve, 
 
 tKeCC  0  
 
where C is the ICG concentration, K (min-1) is the elimination constant and t is 
time in min after administration of the bolus. ICG-PDR (%.min-1) equals Kx100. 
 
Statistical analysis 
Comparison of the two methods (non invasive and invasive measurement of 
ICG) in both groups (finger and nose probe) was done by Bland-Altman 
analysis, reporting mean difference (bias) and Limits of Agreement (LOA, 
bias ± 2 SD).18 Descriptive statistics were generated by the SPSS statistical 








The characteristics of the 41 patients in which the PDD probes were used for 
ICG determination, are presented in table 1. In a subset of 10 patients, 4 males 
and 6 females, 22 dual ICG arterial measurements were taken.  
 









Patients (n) 33 10 8 
Gender (M/F) 11 / 22  4 / 6 1 / 7 
Age (yr) 56.3 ± 18.8 54.2 ± 22.5 42.8 ± 9.6 
Weight (kg) 72.8 ± 12.2 70.8 ± 9.2 65.1 ± 6.5 
Height (m) 1.71 ± 0.09 1.70 ± 0.10 1.70 ± 0.10 




ICG-PDR values in ASA physical status I-II patients 
ICG-PDR measured transcutaneously in 41 healthy patients was 23.1 ± 7.9 
%.min-1 (n=41; 95% confidence interval 7.4 – 38.8). The range was 9.7 – 43.2 
%.min-1. The cumulative frequency distribution and the cumulative normal 
distribution calculated from the mean and standard deviation of the datasets 
measured by both PDD probes are presented in figure 1. 
 
Comparison of transcutaneous and invasive ICG-PDR measurements 
Bland-Altman analysis showed that with the finger probe, PDD overestimated 
ICG-PDR by 1.6 %.min
-1. The limits of agreement (LOA) were -5.2 to 
8.3 %.min-1 (Figure 2, panel A). The relative bias and LOA were 11.6% and      
-31.5 to 54.7% (Figure 2, panel B). Using the nose probe, PDD underestimated 
ICG-PDR by -6.0 %.min-1. The limits of agreement were -15.5 to 3.4 %.min-1 
(Figure 3, panel A). The relative bias and LOA were -23.1% and -57.2 to 11.0% 
(Figure 3, panel B). 
 
 





Figure 1 Cumulative frequency distribution of the values found for indocyanine green 
plasma disappearance rate (ICG-PDR) measured by pulse dye densitometry (PDD) 
(n=41; bullets for finger probe, open diamonds for nose probe) and cumulative normal 





The most important finding of this study is that in our healthy patient population, 
combining 41 non-invasive measurements by finger and by nose probes, the 
mean ICG-PDR was 23.1 %.min-1, with an SD of 7.9 (n=41; 95% confidence 
interval 7.4 – 38.8). The PDD finger and nose probe both performed adequately 
in the noninvasive determination of the ICG concentration.  
 
Study limitations 
We included otherwise healthy patients (ASA physical status I or II) who were 
scheduled for elective surgery. Patients with liver disease were excluded from 
the study based on patient history and physical examination. In 22% of the 
patients liver function tests (aminotransferases) were available and found to be 






Figure 2 Panel A represents the absolute results (bias and limits of agreement 
(= ± 2 SD) from the Bland-Altman analysis of indocyanine green plasma 
disappearance rate (ICG-PDR) measured by the pulse dye densitometry (PDD) finger 
probe or in an arterial blood sample. Panel B represents the relative difference in   
ICG-PDR measurement between the PDD finger probe and from arterial blood. 





Figure 3 Panel A represents the absolute results (bias and limits of agreement 
(= ± 2 SD) from the Bland-Altman analysis of indocyanine green plasma 
disappearance rate (ICG-PDR) measured by the pulse dye densitometry (PDD) nose 
probe or in arterial blood. Panel B represents the relative difference in ICG-PDR 





One may argue that ideally hepatic function testing should have been available 
in all patients. However, none of our patients had a history of hepatic 
dysfunction, showed any signs of hepatic dysfunction during physical 
examination or were scheduled for liver related surgery. Furthermore, patients 
suspected of malnutrition as associated with abnormal body mass index or 
substance abuse including alcohol abuse or any sign of bleeding disorder were 
excluded. 
 
It is known that it is not possible to use ICG-disappearance to discriminate 
between a slight impairment in hepatic cellular function and a change in the 
hepatic blood flow.19 For practical purposes, one of these factors is therefore 
assumed to be constant, in order to interpret changes in ICG-PDR. Changes in 
the ICG-PDR can be caused by alterations in the excretory function of the liver, 
even before changes in serum bilirubin levels are observed.20 A decrease in 
ICG-PDR appears more sensitive in the detection of early liver failure than an 
increase in serum bilirubin level21,22 or critical illness scores like APACHE II.11 
However, generally, changes in ICG-PDR are caused by changes in the 
splanchnic blood flow and thus result from alterations in hepatic blood flow.23 In 
the patients where the nose probe was used, measurements were performed 
during induction with a bolus dose of propofol. During induction changes in 
cardiac output, splanchnic blood flow and mean arterial pressure may occur. 
The results from the nose probe group were evenly distributed among the 
results from the finger probe group, in which measurements were performed in 
patients who were awake and under baseline conditions. This might be 
explained by the fact that the population studied with the nose probe was 
younger and more homogenous than the finger-probe population. The younger 
patients may have a more vigorous compensating mechanism to respond to 
changes in hemodynamics. Since the values found during induction did not 
compose a separate group, we chose to include the data in the representation 
of the ICG-PDR values found in healthy patients. 
 
Ideally, repeated measurements would be performed using both the finger   
and nose probe in the same patient under stable conditions to gather more 
information on the variability of the measurement. Also, changing of 
physiological conditions like volume expansion would be nice to investigate 
further. However, due to the pre-elective surgery setting of the experiments and 
technical limitations, this was not possible. 
 




Interpretation of the results 
We concluded, in agreement with previously published data16,24,25, that the 
PDD finger and nose probe noninvasively determine the ICG decay with a 
relative bias of 12% for the finger probe and -23% for the nose probe. The 
availability of this noninvasive transcutaneous measurement of ICG by pulse 
dye densitometry (PDD) makes ICG-PDR a favorable parameter in the 
evaluation of hepatic flow and/or function. A proper judgment between normal 
and impaired hepatic function or flow then only is realistic in the presence of     
a valid description of ICG-PDR in the healthy population. Up until now the 
normal range of transcutaneously measured ICG-PDR is poorly described17 as 
>18 %.min-1. 
 
We report in our study population of 41 patients without liver disease an      
ICG-PDR of 23.1 (7.9) %.min-1, using noninvasive PDD measurements. Fifteen 
of our 41 patients (37%) had an ICG-PDR of <18 %.min
-1. Ten patients (24%) 
had an ICG-PDR below 16 %.min-1. According to the study of Sakka and 
colleagues11 these persons may have higher mortality. In different studies in 
critically ill patients, or patient after hepatectomy in whom liver failure may      
be expected, adjustment of treatment and fluid administration based on a   
ICG-PDR of <7 %.min-1 or <16 %.min-1 is recommended.2,11 In case of liver 
transplantation, 24 h post-transplantation ICG-PDR values of <18 %.min-1 may 
predict hepatic failure.7 
 
All the above mentioned studies illustrate the search for a clinical 
implementation of ICG-PDR, yet emphasize the difficulties in interpretation. 
Figure 4 illustrates these interpretation problems. Depicted are the cumulative 
normal distribution curves calculated from the means and standard deviations 
of the present surgical study population, the values of a group of patients who 
underwent major hepatectomy without and with postoperative liver failure as 
studied by Sugimoto2 and preoperative patients undergoing liver 
transplantation studied by Faybik.9 In all studies PDD was used to measure 
ICG-PDR. We have chosen these studies as they offer ICG-PDR data from 
patients with normal hepatic function, and patients with reduced and severely 
reduced functional liver tissue, respectively. The results in these studies are 
represented as mean and standard deviation; this is only valid if the results are 
normally distributed. We assumed the authors tested their data for normal 
distribution and simulated the data based on the reported mean and standard 
deviation. As can be observed from figure 4 a decrease in functional liver tissue 
not only decreases the mean ICG-PDR but also concurs with a decrease in 
variation around the mean, indicated by an increased steepness of the 





the distribution curve stretches to the right, but maintains its origin at a value 
below 10 %.min-1. This has implications for the ability of ICG-PDR to detect 
differences between patient groups. At any chosen threshold, ICG-PDR value 
groups will be easier distinguished if the distance between their curves at that 
value of ICG-PDR is larger. Obviously patients with terminal liver failure or with 
a decreased but survivable liver function after hepatectomy can be best 
discriminated from healthy patients around an ICG-PDR of 7.5 %.min-1. 
Similarly, the reduction in ICG-PDR of surviving post-hepatectomy patients in 
comparison to healthy patients is best observed around an ICG-PDR of about 
20 %.min-1, as the distance between their curves is largest. Since the distance 
between these curves is diminished their distinction will be hindered by a 
decreased sensitivity and specificity. 
 
Figure 4 Cumulative frequency curves calculated from the mean and average of the 
present study (small dash), patient without (dash-dot-dash) and with liver failure (long 
dash) developing on the first day after major hepatectomy studied by Sugimoto2 and 




We used receiver operating characteristics (ROCs) to further explore this 
subject, and this is represented in figure 5. The simulated patient populations 
from the 2 studies were compared to our healthy population to determine the 
ICG-PDR cutoff value with the highest sensitivity and specificity to identify the 




affected patients. Taking into consideration all noninvasive measurements of 
ICG-PDR, the patients with liver failure in the study of Faybik would be best 
identified from our healthy patients, if a cutoff value for ICG-PDR of < 9 %.min-1 
would be used, with a sensitivity of 98.5%, a specificity of 96.3%, and an AUC 
under ROC curve of 0.99 (Figure 5, panel A). Similarly, the patients with 
terminal liver failure after hepatectomy would be detected with a sensitivity of 
98.7% and a specificity of 93.7% if a ICG-PDR value < 11 %.min-1 would be 
used. The AUC under the ROC curve is 0.99, indicating good accuracy 
(Figure 5, panel B). To detect decreased liver function of the patient surviving 
hepatectomy in the study of Sugimoto compared to our healthy patients the 
detection level would have to be set to ICG-PDR < 19 %.min-1, but the 
sensitivity would only be 69.8% and the specificity 82.4%. Similarly, the AUC 
under the ROC curve indicates only moderate accuracy with a value of 0.82 
(Figure 5, panel C). Our exploration suggests that terminal liver failure can 
adequately be detected with ICG-PDR, but non-terminal decrease of liver 
function is harder to detect. This is supported by the finding of Sugimoto that 
they were unable to discern patients that would experience liver failure after 
major hepatectomy using preoperative ICG-PDR values. On the other hand, 
Hori and co-workers7 were able to detect differences in a homogeneous group 
of post liver transplant patients as soon as 24 h after transplantation between 
patients with good outcome (ICG-PDR of 21.0 ± 2.4 %.min-1), (mean ± SD) and 
bad outcome (ICG-PDR of 16.3 ± 2.1 %.min-1), (mean ± SD). We suggest that 
this finding is the result of the relative homogeneity of their study group and the 
accompanying diminished variability of their ICG values.  
 
In conclusion, we evaluated the transcutaneous measurement and defined the 
absolute value of the ICG-disappearance rate by PDD in an otherwise healthy 
group of patients scheduled for general non-hepatic surgery. The PDD finger 
and nose probe showed a relative bias of 12% and -23% respectively, 
compared to the measurement of ICG-PDR in arterial blood. Within this healthy 
population the mean ICG-PDR was 23.1 %.min-1 (95% confidence interval 
7.4 – 38.8), which is more variable than the value of >18%.min-1 which is 
usually referred to as normal value. Variability in transcutaneous measurement 
is probably larger than by intravascular fiberoptic measurement. We suggest 
that a broader evaluation of noninvasive measurement of ICG-PDR in the 
healthy population is warranted, before this parameter is used as a 










Figure 5 Representation of ROC curves (solid line) and the area under the curve 
versus the ICG-PDR value (dashed line) of three study populations. In panel A test 
results for the detection of liver failure in a population undergoing liver transplantation 
from the study of Faybik9 are used. An ICG-PDR cut-off value of 9%.min-1 generates 
the optimum sensitivity and specificity in this population. In panel B test results for the 
detection of liver failure in a population undergoing major hepatectomy from the study 
of Sugimoto2 are used.An ICG-PDR cut-off value of 11%.min-1 generates the optimum 
sensitivity and specificity in this population. Panel C represents the results from the 
population experiencing only decreased liver function after mayor hepatectomy, also 
from the study by Sugimoto2. The cut off value of 19 %.min-1 is much less accurate. 
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For drugs with rapid onset of action, such as rocuronium, an understanding of 
the factors governing distribution kinetics is crucial. Although it has been shown 
in previous studies that rocuronium, like other muscle relaxants, distributes only 
in the plasma and interstitial fluid volume, the mechanism of the distribution 
process is not fully understood. One would suggest that the interstitial 
distribution of rocuronium resembles that of inulin, a marker for extracellular 
water, but this is not yet clear. Conventional compartmental models are not 
suitable to answer such questions due to the assumption of instantaneous drug 
mixing in the compartments. While recirculatory models with compartmental 
structure characterize the initial phase of vascular mixing well and explain the 
role of cardiac output as determinant of effect onset 1,2, they are inadequate to 
directly characterize the tissue diffusion of drugs. 
 
In order to overcome these limitations, a model based on first principles, 
namely the basic processes of drug distribution in the body, advective transport 
by blood flow (vascular mixing) and diffusion into extravascular space, has 
been developed. This minimal physiological model in which the lumped organs 
of the systemic circulation were described by an axially distributed capillary-
tissue exchange model3 has been applied successfully to analyze the 
distribution kinetics of inulin, antipyrin4 and thiopental5 in dogs. An important 
feature of this approach is that the use of indocyanine green (ICG) as vascular 
marker allows a clear distinction between intravascular mixing and tissue 
diffusion (multiple-indicator method). Analysis of disposition kinetics of 
rocuronium is based on the information on mixing in the vascular system 
obtained from the distribution kinetics of ICG. Concomitant injection of a 
vascular marker (e.g., ICG) with the drug followed by frequent sampling of 
arterial blood is thus a prerequisite for the application of this modeling 
approach. The theory of transit time distributions is an adequate mathematical 
approach because it is independent of a specific model of drug distribution 
kinetics. 
 
Using the ICG and rocuronium disposition data measured in patients 1, the goal 
of this study was: 
 
1. to examine vascular mixing in terms of cardiac output and transit time 
dispersion6,  





3. to estimate the parameters with a population approach. The lack of 
population recirculatory models has been noted in a review on 





Data and Study Protocol 
The experimental protocol, including sampling method, has been described 
before.1 To summarize: datasets from ten healthy female patients undergoing 
eye surgery under general anesthesia after providing written informed consent 
were evaluated. Premedication, midazolam 7.5 mg orally, was given 60 min 
prior to induction of anesthesia by target controlled infusion of propofol (target 
at 4 µg/ml) and remifentanil (adjusted according to the surgical condition). After 
loss of consciousness, rocuronium 0.35 mg/kg was injected intravenously for 
muscle relaxation. Rocuronium (10 mg/ml) was injected as a mixture with ICG 
(25 mg) and autologous blood in a total volume of 10 ml. Of this mixture 9 ml 
were administered and 1 ml was used for a-posteriori measurement of injectate 
concentrations. 
 
Blood samples were taken from a cannula in the radial artery. During the first 
10 minutes of the experiment, sampling was performed using a custom made 
computer controlled syringe pump and fraction collector for determination of 
ICG and rocuronium concentrations. In the first minute, a blood sample was 
taken every 3 s, followed by sampling every 10 s in the second minute. 
Consecutive samples were taken at 2.5, 3, 4, 7, and 10 min. Hereafter samples 




ICG concentrations were measured spectrophotometrically at 850 nm in whole 
blood. Each patient’s whole blank blood with added amounts of ICG was used 
for construction of a reference line. The measured absorption at 850 nm minus 
the absorption in the sample taken before the experiment was considered to be 
caused by ICG. Rocuronium concentrations were measured in whole blood by 









The structure of the circulatory pharmacokinetic model based on advective 
transport to the organs and diffusion within organs is shown in figure 1. It 
consists of two heterogeneous subsystems, the pulmonary circulation which 
includes the lungs and the heart chambers and the systemic circulation where 
all organs are lumped together. This model has been described in detail 
previously.4 
 
Figure 1 Schematic representation of the circulatory model. The capillary network of 
organs (indicated by parallel tubes) lead to transit time heterogeneity (dispersion) of 
vascular marker. All organs of the systemic circulation are lumped together. The blood 
and tissue volumes of the pulmonary and systemic circulation, respectively, are 
indicated. Diffusional transport into the tissue space characterized by the diffusional 
equilibration time d is illustrated in an infinitesimal small volume element since the 
model contains no well mixed spaces. The clearance is defined as product of systemic 
extraction ratio (E) of the drug and cardiac output (CL= EQ). (For the definition of 
parameters, see table 1.) 
 
 
Briefly, the subsystems are characterized by transit time density (TTD) 

















from the ICG disposition data. The respective parameters are cardiac output Q, 
the vascular (blood) volumes VB,p ,VB,s and the relative transit time dispersion 
RD2B,p, RD
2
B,s, of each subsystem. (The index i = p and s labels the pulmonary 
and systemic circulation). A lag-time Tlag was introduced to account for the 
delayed first appearance at the sampling site. These parameters are 
incorporated into the axially distributed capillary-tissue exchange model, used 
for diffusion of rocuronium into the extravascular (tissue) space with distribution 
volumes VT,p ,VT,s and diffusional equilibration time d, the characteristic time 
constant of the interstitial diffusion process that is determined by the effective 
tissue diffusion coefficient Deff and the characteristic diffusion path length L 
(d = L2/Deff). The apparent permeability surface area product PSdiff , defined as 
PSdiff = VT,s /d, is a measure of PS averaged over all organs and combines all 
of the diffusive transport processes into a single “lumped” parameter. Note that 
the steady state distribution volume Vss is obtained as the sum of all distribution 
volumes of rocuronium, Vss=VB,p+VT,p+VB,s+VT,s. The model equations fitted to 
the data are summarized in the Appendix. 
 
For comparison, the rocuronium data were also fitted using the conventional 
two-compartment-model. On the basis of the parameter estimates V1 (volume 
of the central compartment), V2 (volume of the peripheral compartment), CL12 
(distribution between V1 and V2) and CLroc (clearance), and the distribution (or 
mixing) clearance CLM as a model-independent measure of whole body 
distribution kinetics was calculated as8 
 




Population pharmacokinetic analyses were performed with maximum likelihood 
(ML) estimation (no linearizing approximations) via the expectation 
maximization algorithm (EM) using the program MLEM implemented in the 
software package ADAPT 5.9 The program provides estimates of the 
population mean inter-subject variability, and standard errors (%RSE) for the 
maximum likelihood estimates, as well as of the individual subject parameters 
(conditional means). The residual (error) variance model described the 
observation standard deviation as linear with the fitted value C(t) as follows: 
var[εi(t)] = [σ0 + σ1C(ti)]
2 , where σ0 and σ1 are the variance parameters. 
‘Goodness of fit’ was assessed using the Akaike Information Criterion and by 
plotting the predicted versus the measured responses. First, the ICG data were 
fitted (Appendix, Eq. 2), then the estimates of Q, VB,p ,VB,s, τlag, RD
2
B,p and 




RD2B,s for the individual subjects (conditional means) were fixed in fitting the 
rocuronium data (Appendix, Eqs. 2 and 4). Body weight was investigated as 
covariate in the analysis. Since compartmental analysis is based on a well-
mixed central compartment, only data observed after complete circulatory 
mixing (t > 1.3 min) were included when applying this model. 
 
The dependencies of parameters from cardiac output were analyzed using 





The population parameters for ICG are summarized in table 1. That %RSE was 
not available for ICG parameters is due to the relative large number of 
adjustable parameters (7) compared to the number of subjects (10) (whereas 
only 4 parameters were estimated for rocuronium). 
 
The individual fits (based on conditional estimates) are characterized by an 
R2 of 0.94 ± 0.03. The observed and predicted pharmacokinetic profiles are 
depicted in figure 2, panel A for a subject with a R2 value that was closest to 
the group median value. The plot of the individual predicted versus observed 
concentrations (Figure 2, panel B) demonstrates that the data are well fitted by 
the model. 
 
Systemic transit time heterogeneity (RD2B,s) decreased with increasing cardiac 
output (Figure 3) and central blood volume (VB,p) increased with cardiac output 
(Figure 4). The clearance of ICG was significantly correlated to cardiac output 
(CLicg = 0.144 + 0.15Q, R
2 = 0.5, p<0.05). 
 
The rocuronium parameters VT,p ,VT,s, d and CLroc estimated with the circulatory 




B,s) held fixed are also 
depicted in table 1. An individual fit and the goodness-of-fit plot are shown in 
figures 5, panel A and panel B. The individual fits are characterized by an R2 of 
0.89 ± 0.08.  
 
Although an extension of the model5 by addition of the pulmonary interstitial 
space (VT,p) improved the fit, it was not estimated as well as the other 
parameters. Inclusion of weight as covariate did not improve the model in this 






The parameter estimates for rocuronium obtained using a two-compartment 
model were: Vss = 20 ± 3 L, CLroc = 0.449 ± 0.023 L.min
-1 and CLM = 0.84 
± 0.37 L.min-1. The latter increased significantly with cardiac output (slope = 
0.35, p<0.05). 
 
Table 1 Patient Parameter estimates for the model of rocuronium distribution kinetics 
based on circulatory mixing (ICG) in patients under propofol anesthesia (n = 10). 
 







ICG   
Lag time, τlag (min)* 0.124 9 
Cardiac output, Q (L.min-1)* 3.52 20 
Pulmonary blood volume, VB,p (L)* 1.94 18 
Relative dispersion of pulmonary circulation, RD2B,p* 0.090 12 
Systemic blood volume VB,s (L)* 1.84 24 
Relative dispersion of systemic circulation, RD2B,s* 0.367 21 
Clearance, CLICG (L.min
-1) 0.669 27 
Rocuronium   
Interstitial diffusional equilibration time, d (min) 89.0 (37) 50 (62) 
Pulmonary extravascular volume of distribution, VT,p (L) 2.66 (97) 115 (61) 
Systemic extravascular volume of distribution VT,s (L) 14.2 (30) 29 (96) 
Clearance, CLroc (L.min
-1) 0.449 (24) 24 (75) 
Apparent permeability surface area product  
PSdiff = VT,s /d, (L.min
-1) † 
0.159 92 
Steady state volume of distribution, 
VSS = VB,p +VT,p+ VB,s+VT,s , (L)
† 
20.7  24 
Distribution clearance (Appendix, Eqs. 5 and 6) CLM 
(L.min-1) † 
0.63 42 
Residual Error, σ1(%)   
ICG 15.4  
Rocuronium 27.1  
 
*Corresponding individual estimates were used as fixed parameters in fitting rocuronium data. 
†Derived parameters 





Figure 2 (A) Fit of the time course of arterial ICG concentration in one subject and (B) 
goodness of fit plot, showing the model-predicted data versus observed data. The 














































































































 Figure 3 Systemic transit time heterogeneity of ICG (RD2B,s) decreases linearly with 




Figure 4 Central blood volume (VB,p) increases linearly with cardiac output (Q) with a 






































































































Figure 5 Fit of the time course of arterial rocuronium concentration in one subject (the 
inset shows the early phase in more detail) (A) and goodness of fit plot (B), showing 
the model-predicted data versus observed data. The solid diagonal line represents the 



















































































































































In order to gain better understanding of the distribution kinetics of drugs with a 
rapid time-to-onset, a model based on intravascular mixing and capillary-tissue 
exchange was applied to the muscle relaxant rocuronium. The results show 
that circulatory models based on transit time theory overcome the structural 
limitations of compartmental models since no well-mixed spaces are assumed. 
As expected from previous studies in dogs, vascular mixing of ICG in patients 
was well described by the recirculatory model based on empirical transit time 
distributions10 and the extension of this model to include diffusion into tissue4 




Circulatory mixing is the first step in drug distribution kinetics. Since the 
parameters of the present model have a definite physiological meaning, the 
analysis of ICG disposition in patients reveals some interesting insights. First, 
we found significant correlation between cardiac output and cardiopulmonary 
volume (Figure 4). This has been observed previously, albeit for a much larger 
span of cardiac output, including hypertensive patients11,12 and during exercise 
in healthy subjects.13 Apparently the cardiopulmonary volume is a good 
estimate of cardiac filling and thus correlates with cardiac output.14 
 
Second, systemic transit time dispersion decreases with increasing cardiac 
output (Figure 3). This reduction in heterogeneity of blood transit time through 
the systemic circulation may result from a redistribution of blood flow to organs 
and/or a more homogeneous transit time distribution in organs (e.g., skeletal 
muscle).10 Note that the heterogeneity of transit time distribution through an 
organ is based on the fact that some molecules may by random chance 
traverse the complex capillary network more quickly than others. There are no 
previous reports about the relationship between systemic transit time 
dispersion and cardiac output. Interestingly, however, exercise decreased 
transit time heterogeneity in human skeletal muscle15 as well as lungs16 and 
this effect was explained by vascular recruitment and dilatation. Further 
clarification of the mechanism underlying the changes in systemic transit time 
dispersion remains an interesting topic for future studies. The above account 
shows that our modeling of the ICG data can provide quantitative information 
on the hemodynamic status of the patient. Our estimate of vascular pulmonary 
transit times dispersion (RD2B,p = 0.09) is in good agreement with that of 0.08 
estimated using first-pass technetium 99m albumin angiocardiography.17 While 




no estimates of the systemic transit time dispersion of vascular markers are 
available in the literature, it may be noteworthy that our estimate of RD2B,s is in 
the range of 0.2 to 1, where simulation suggests very rapid circulatory mixing.6 
 
The estimates reported here for the model-independent parameters ICG 
distribution volume, clearance and cardiac output are consistent with those 
obtained previously1 using a different modeling approach. The finding that 
clearance of ICG increased significantly with cardiac output can be explained 
by the relative high hepatic extraction of ICG, which makes clearance highly 
dependent on hepatic blood flow. Assuming a fractional liver blood flow of 25%, 
a hepatic extraction ratio of 75 ± 14 % was calculated, which is in accordance 
with the value of 78% measured in humans.18 
 
One should bear in mind that the pharmacokinetics of rocuronium described by 
this model are derived from data measured in patients under general 
anesthesia with propofol in a concentration likely to cause vasodilation and 
cardiodepression. The influence of propofol on the pharmacokinetics of opioids 
and sedatives has been described before.19-21 On the other hand, it is not 
ethical to gather data on muscle relaxants in non-sedated patients. 
 
Interstitial distribution 
Permeation across the capillary wall and interstitial diffusion governs 
extravascular distribution of rocuronium. In the present diffusion-limited model, 
the parameter d defines the rate of distribution (diffusional time constant), and 
can be interpreted as a phenomenological parameter that takes into account 
both transcapillary permeability and interstitial diffusivity. It appears that the 
latter is the rate limiting process.22 That the value of d = 89 min estimated here 
for rocuronium in humans, is in the same order of magnitude as that of 51 min 
for inulin, a prototype of a hydrophilic drug, obtained in dogs4, indicates that  
rocuronium distributes into the interstitial space by passive diffusion like inulin. 
A direct comparison is difficult  since apart from the species differences, 
rocuronium, in contrast to inulin, is plasma-protein bound with a free fraction of 
42 % 23 and has an higher apparent diffusion coefficient than inulin.24,25 
However, the much shorter diffusion time d of antipyrine compared to inulin 
(3 vs 51 min) estimated in dogs, which can be explained by the 40-fold higher 
effective tissue diffusion coefficient of antipyrine4, suggests that rocuronium 
undergoes a diffusion limited distribution rather than a flow-limited distribution 
like antipyrin. The resulting whole-body distribution kinetics of rocuronium        
is characterized by an apparent permeability surface area product, PSdiff = 





the results obtained for inulin and antipyrine in dogs with the same approach4 
speaks for the validity of this estimate. Thus, the apparent PSdiff of 0.27 L.min
-1, 
which was estimated for inulin in dogs4, is quite similar to that of 0.33 L.min-1 
for inulin measured in human forearm muscle.26 Furthermore, the interstitial 
diffusional equilibration time estimated with our modeling approach in vivo 
appears to be in agreement with in vitro measurements.27 
 
The distribution or mixing clearance CLM, defined as a measure of overall rate 
of drug mixing into their distribution volumes8,10; the values of 0.68 L.min-1 
obtained from the parameters of the diffusion model (Eq. 6) and of 0.84 L.min-1 
obtained from the compartmental model (Eq. 1), respectively, are less than 
cardiac output. The difference can be explained by the fact that the 
compartmental CLM (Eq. 1) is defined as distribution out of an empirical central 
compartment (which has no physiological counterpart), whereas in the present 
model CLM characterizes the distribution of rocuronium out of the vascular 
space in the systemic circulation (Eq. 6). For the latter, no significant correlation 
with cardiac output was found (in contrast to the compartmental CLM). The CLM 
for unbound rocuronium is quite similar to that of sorbitol, a marker for 
extracellular water, in humans, for which a correlation with cardiac output was 
found.28 Note that an increase of CLM with a moderate increase in cardiac 
output would not be in contrast to the assumption of diffusion-limited tissue 
distribution, since there is a continuous transition from diffusion-limited to flow-
limited distribution kinetics.4 
 
We found that the volume of distribution of rocuronium (Vss = 20.7 L) was 
higher than that previously estimated of 17.3 L1. This difference may be due to 
the fact that the present model also accounts for distribution into lung tissue 
(VT,p = 2.7 L). Since the pulmonary distribution volume of rocuronium is higher 
than that of ICG, the mean transit time across the lungs is also somewhat 
higher by 0.8 ± 0.6 s, which is in accordance with the value of 1 s reported in 
pigs.29 That the distribution volume of rocuronium (Vss) is similar to that 
reported for the interstitial space (e.g., Ref. 30) suggests that its tissue binding 
is of the same degree as the plasma protein binding (with a free fraction          
of fu = 0.42)23. Interestingly, but not unexpected for model-independent 
parameters, our estimate of rocuronium clearance is nearly identical with that 
determined previously.1 The same holds for our estimates of Vss and CLroc 
(Table 1) and those obtained with the two-compartment model Vss (20 ± 3 L) 
and CLroc (0.449 ± 0.023 L.min
-1). Note that due to the differences between the 
present and alternative models with respect to model structure, only those 
parameters could be compared that were independent on the specific structure 
of the model. For example, there is no counterpart of transit time dispersion      






B,s,) or diffusional equilibration time (d) in the other models. Since 
in the alternative recirculatory model1,2 the systemic circulation consists of 
parallel well-mixed compartments, it does not provide direct information on 
interstitial diffusion. 
 
Finally, it should be recalled that the validity of a model is determined by the 
modeling objectives.  Thus, it was not the goal of this study to improve the fit of 
the rocuronium data (relative to that obtained in Ref. 1), but rather to 
understand better the role of vascular mixing (transit time dispersion) and 
interstitial diffusion. Since the fit of the rocuronium data was already quite 
optimal in the previous study1, we did not repeat the PK-PD analysis. Given the 
fact that the empirical PK-PD link model is based on the time course of plasma 
concentration, no improvement could be expected. Furthermore, it is obvious 
that for rocuronium a classical compartmental model is appropriate for 
estimation of parameters like Vss and CL, which are independent of a specific 
model structure (only based on the assumption that the rate of drug elimination 
is proportional to the sampled drug concentration). 
 
Like all models, our approach is based on simplifying assumptions that may 
lead to certain limitations. Thus, the goodness of fit plots (figures 2 and 5, 
panels B) are partly non-symmetric around the lines of identity, indicating a 
non-optimal fit near the recirculation peak. A possible reason for this may be 
that the systemic transit time distribution (single subsystem), in contrast to 
parallel channels1,2,31, does not sufficiently account for a shunt flow. 
Furthermore, the estimation of clearances is based on the assumption of 
constant systemic extraction ratios. Since ICG is completely and rocuronium 
predominantly eliminated by the liver, this implies the assumptions of a 
constant fractional liver blood flow and a hepatic extraction ratio, which is blood 
flow independent. 
 
In conclusion, this study demonstrates the applicability of the transit time 
dispersion based model of vascular mixing and the diffusional tissue 
distribution model4 in clinical pharmacokinetics. It accounts for the roles of 
circulatory mixing and diffusion into the interstitial fluid in determining the 
distribution kinetics of rocuronium, and thus sheds new light on our 
understanding of underlying transport physiology. Future applications may 
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As derived in Ref. 10, the Laplace transform of the solution to the circulatory 
model for a vascular indicator          , i.e. of the concentration-time curve C(t) 
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where and are the Laplace transforms of pulmonary and 
systemic transit time density (TTD), described by the density function of the 
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Q and CL denote cardiac output and clearance. The parameters in Eq. 3 are 
the blood volumes VB,p ,VB,s and the relative transit time dispersion RD
2
B,p 
RD2B,s, of the pulmonary and systemic circulation. For fitting the C(t) date of a 







     (4) 
 
where d is the characteristic time constant of the diffusion process4 . 
 
In other words, and in Eq. 2 are replaced by: 
the TTDs and for rocuronium which are obtained by adding 
an extra term to s, as outlined in Eq. 4. Since the model equations for data 
fitting are only available in the Laplace domain, we incorporated a method of 
numerical inverse Laplace transformation32 into the model file (Fortran) of 
ADAPT 5.9 
 
As secondary parameter the distribution clearance into the tissues of the 
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The pharmacology of the induction of anesthesia is still poorly understood and 
often roughly described using compartmental modeling. The inability to 
describe and predict the plasma concentration of a drug like propofol during 
induction of anesthesia may lead to under- or overdosing in various patient 
groups, leading to insufficient anesthetic effect or undesired side effects and is 
a problem that has been recognized in the anesthetic field.1 
 
In contrast to compartmental modeling, the early disposition of induction agents 
may be better described using physiological based modeling techniques like 
recirculatory modeling, as is described in chapter 2 of this thesis. Unfortunately, 
for intravenous anesthetics data on this type of modeling are still scarce. Within 
the short timeframe of the induction of anesthesia the importance of cardiac 
output as driving force of drug distribution is generally accepted, while the role 
of the lung as a modulator of the peaks and troughs in blood drug concentration 
is still poorly understood. This is especially the case for the disposition of 
anesthetic agents in humans. 
 
The role of the lung as a pharmacological entity that modulates drug 
disposition, biotransformation and elimination can be studied in vivo by 
inclusion of the lung as a separate compartment within the central blood 
compartment.2 The central blood compartment includes the intravascular 
volume of the heart and the lungs combined, as well as that of the central 
arteries. Ideally, the characteristics of such a compartment are best studied 
when the drug concentrations (and metabolites) are measured in the volumes 
before, after and from the compartment itself.  
 
The fast-acting intravenous hypnotic agent propofol is known to be primarily 
cleared and metabolized in the liver, but is also known to undergo renal 
metabolism and excretion.3-5 The lungs play a significant role in the uptake of 
propofol, but so far, discrepancy6-8 remains on the significance of metabolism 
of propofol in, or excretion from, the lungs. Because propofol is a volatile and 
highly lipophilic agent, diffusion into the alveoli after disposition in the 
pulmonary tissues is likely. This assumption has proven realistic9-13, now that 
propofol is detected in the expired air, although the actual expired propofol 
concentration still remains difficult to quantify. 
 
The scarcity of recirculatory data on propofol in humans and the uncertainty of 





pharmacokinetics of propofol in healthy patients during induction of anesthesia. 
The aim of this study was 3-fold: 
 
1. To describe the early-phase pharmacokinetics of propofol in humans. 
2. To determine the role of the lung in the clearance and distribution of 
propofol. 
3. To compare the predictive accuracy of a recirculatory pharmacokinetic 
model for propofol with compartmental models from the literature, which 
are used in daily practice to predict the blood propofol concentration 






The study was performed after approval of the Medical Ethics Committee of the 
Leiden University Medical Centre and written informed consent. Ten patients, 
ASA status I or II scheduled for elective surgery were included in the study. 
Exclusion criteria included a BMI>30, a medical history of severe 
cardiovascular, respiratory, renal, hepatic, neurological or psychiatric disease, 
use of anti-hypertensive or anti-arrhythmic medication, pregnancy or lactation 
and a history of hypersensitivity to ICG. 
 
Procedures 
Prior to the study a cannula was inserted in a large vein in the fossa cubiti for 
fluid and drug administration. The radial artery was cannulated for the collection 
of arterial blood samples and intra-arterial blood pressure measurement and 
cardiac output monitoring through arterial pulse contour analysis with the 
LiDCO (LiDCO plus, LiDCO Ltd, Cambridge, UK). At every heart beat the 
arterial systolic blood pressure (SBP), diastolic blood pressure (DBP), mean 
arterial pressure, heart rate, cardiac output and stroke volume were gathered, 
provided the arterial cannula was not used for blood sampling. Peripheral 
oxygen saturation and pulse rate was measured using a finger probe. A second 
finger probe was applied for the transcutaneous measurement of ICG (DDG 
2001, Nihon Kohden, Japan). Sedative data were gathered using the bispectral 
index score (BIS) (A-2000, Aspect Medical Systems, USA); the raw and 
processed electroencephalogram (EEG) data were transferred to a laptop 
computer every second. ECG monitoring was applied as well. Control blood 
samples were taken for the construction of reference aliquots and 




determination of the hemoglobin level and sodium content, needed for the 
calibration of the LiDCO and DDG monitor. The LiDCO monitor was calibrated 
before each experiment by intravenous administration of 0.2 mmol lithium. The 
LiDCO monitor calibration was based on the non-invasive online determined 
arterial lithium concentration-time curve and the cardiac output calculated. The 
LiDCO has been studied and found acceptably reliable in cardiac output 
monitoring, when compared with traditional thermodilution cardiac output 
monitoring for up to 8 h after calibration (LidCO versus thermodilution: 
r = 0.86).14,15 
 
Before the start of each experiment, baseline measurements of the arterial 
blood pressure, heart rate (HR), cardiac output (CO) and BIS were recorded for 
at least 15 min. After 3 min of preoxygenation with 100% O2, each session 
started with the rapid intravenous administration of propofol 3 mg.kg-1, mixed 
with 10 mg of ICG (Infracyanine®, Laboratoire SERB, France). The 
propofol/ICG bolus was immediately followed by a rapid bolus of 20 ml of 
NaCl 0.9%. A computer-controlled syringe pump combined with a fraction 
collector was programmed to draw 37 arterial blood samples in the first 2.5 min 
after propofol administration at 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 
42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 100, 110, 120, 
130, 140, and 150 sec. Due to the construction of the sampling device, no 
mixing in the tubing could occur, as has been described before16 (Figure 1). 
Five more blood samples were drawn manually at 3, 4, 5, 7.5 and 10 min after 
administration of the ICG bolus dose. During manual sampling, a waste sample 
was drawn first. The blood samples were collected in heparinized glass tubes 
and processed immediately. 
 
Measurements of ICG and propofol in blood  
The concentrations of ICG and propofol were determined in series in heparin 
whole blood using High Performance Liquid Chromatography (HPLC) 
(Separations analytical instruments, Hendrik-Ido-Ambacht, The Netherlands; 
column: Ultrasphere ODS 4,6 x 7.5 cm 244254, Beckman Coulter, Mijdrecht, 
The Netherlands) with ultraviolet and fluorescence detection for respectively 
ICG and propofol. Thymol was used as the internal standard for both 
compounds and was measured by fluorescence detection. For each patient a 
calibration curve was constructed, using the patients own blood prior to 
injection of ICG and propofol. The blood was deproteinized with acetonitril and 
the supernatance was injected on the HPLC. The fluorescence settings were 
as follows; excitation at a wavelength of 275 nm and the emission wavelength 





785 nm, its peak in the spectrum, on the PDA 100. Both ICG and its 
degradation product were identified by this diode array (Photodiodedetector 
PDA 100, Dionex, Amsterdam, The Netherlands). The detection limit of         
the whole blood assay for ICG was at 0.2 mg.L-1 and at 0.5 mg.L-1 for    
propofol. The coefficient of variation was less than 8 % over the range from 0.5 






Figure 1 Schematic representation of the syringepump, in which the tubing and 
stopcock construction is represented. Since the volume that is aspirated by the syringe 
equals the volume in the tubing, no mixing of the blood samples can occur. 
 
 
Data collection and processing 
BIS and raw EEG data were transferred to a laptop and imported into a 
spreadsheet program (Excel 2000, Microsoft Corporation, Seattle, U.S.A.). The 
same applied for the hemodynamic data derived from the LiDCO monitor, 
including arterial blood pressure and cardiac output, as well as for arterial blood 
ICG-concentrations, to undergo further analysis. 
 





A recirculatory model, in analogy to the model described for determination of 
lung uptake and pulmonary clearance of propofol in sheep17and explained in 
chapter 2 of this thesis, was constructed using the indicator ICG to estimate the 
intravascular compartment. The model for ICG contained a central part, 
consisting of two parallel pathways, modeled by n tanks-in-series (Figure 1). To 
account for the delay observed between injection of the bolus ICG and the 
detection of any amount of ICG, a lag-time was incorporated into the model as 
an extra delay element: Tlag. Cardiac output was calculated by dividing the 
administered ICG dose by the area under the first pass concentration-time 
curve (A1+A2; see below). The shape of the first pass concentration-time curve, 
including all data before evidence of ICG recirculation, was described by        
the sum of two Erlang functions, each representing the convolution of n           



























where n1 and n2 are the number of compartments in series in the central delay 
elements; k1 and k2 are the rate constants between the compartments in series; 
n1/k1 and n2/k2 are the mean transit times of the central delay elements; A1 and 
A2 are the areas under the first pass concentration-time curves. The two Erlang 
functions were fitted to the data using the solver function in Excel (Microsoft 
Corporation, Seattle, U.S.A.), whereby data were uniformly weighted. The lag-
time and parameters simulating the first-pass curve (Tlag, VC(f+s) and MTTC(f+s)) 
were then transferred to the SAAM program (SAAM II, version 1.1.1, SAAM 
Institute, University of Washington, USA) to further analyze the peripheral part 
of the systemic circulation, including recirculation. This part consisted of two 
parallel pathways as well, defined by their respective volumes (VND(f+s)) and 
clearances (ClND(f+s)). Combined with the elimination clearance ClEL the 
summed clearances equaled the cardiac output. 
 
The model for propofol was constructed in a similar way, meaning that the data 
before recirculation of ICG were fitted by two Erlang-functions. The lag-time 
was fixed from the ICG data. Then, the parameters were transferred to the 
SAAM program. For the model of propofol a single tissue compartment was 
added, in analogy to drug modeling described by Henthorn et al.19, since only a 
short period after recirculation was studied (Figure 2). The ratio between the 





this ratio determined for ICG. Lung retention at first-pass was determined as 
described before.20,21 
 
Comparison to other pharmacokinetic datasets  
For comparison of the accuracy of the pharmacokinetic parameters found in 
this study in relation to the pharmacokinetic parameter sets reported in 
literature, the 2 parameter sets were selected that are clinically used in the 
target controlled infusion (TCI) systems for propofol and are commercially 
available. These are the parameter set described by Marsh23, which is 
incorporated in the Diprifusor® system (AstraZeneca), and the parameter set 
described by Schnider24, which is incorporated in the Orchestra Base Primea® 
system (Fresenius Kabi ltd). For both pharmacokinetic parameter sets the 
predicted plasma concentration-time curve of propofol was simulated, based on 
the administration of an instantaneous bolus of 201.3 mg of propofol to a 
woman of 42 years of age, weighing 67 kg, and with a length of 1.72 m (our 
average patient with the average dose administered). Simulation was 





Figure 2 Intravascular part of the recirculatory model, used to fit the ICG data. The 
model consists of a delay element representing the venous lag time (Tlag), two parallel 
central pathways represented by a varying number of tanks-in-series (a fast VC-f and 
slow VC-s) and two parallel non-distributive peripheral compartments (a fast VND-f and 















Descriptive statistics were generated by the SPSS statistical package (SPSS, 
version 17). Parameters were tested for normality using the Kolmogorov-
Smirnov test. Any parameter that was not normally distributed was tested for 
normal distribution after log transformation. If the log transformed parameters 
proved to be normally distributed, the mean and standard error of the 
mean (SEM) were thereafter transformed back using the following equations: 
mean = eµ+σ^2/2n and SEM = √((eσ^2/n-1)e2µ+σ^2/n). Linear regression analysis  
was performed using the same statistical package. Statistical significance    







The 10 patients included were 2 males and 8 females, who were aged 
42.2 ± 8.7 yr, weighed 67.1 ± 11.8 kg, were 1.72 ± 0.1 m with a body mass 
index of 22.5 ± 2.2 kg.m-2. The induction of anesthesia with the intravenous 
bolus dose of propofol (3 mg.kg-1) resulted in a rapid loss of consciousness in 
all patients with a lowest BIS of 24 ± 9, measured at 75 (60-115) seconds 
(median and range) after the intravenous administration of propofol. All  
patients had to be ventilated by mask. With again decreasing blood propofol 
concentrations and sedative levels, BIS reached a mean of 72 before the data 
collection was terminated. Data collection was terminated after sufficient data 
was gathered to allow recirculatory modeling of propofol pharmacokinetics but 
before return to consciousness. After termination of the study, anesthesia was 
continued with propofol, remifentanil and atracurium and the trachea was 
intubated. The patients then were ready for their scheduled surgical procedure. 
The study was completed without any adverse event. No patients reported any 
signs of awareness. All blood samples were analyzed within 12 weeks. 
 
The mean peak arterial plasma ICG and peak arterial blood propofol 
concentration occurred at 18 and 21 sec past administration, respectively, 
reflecting the equally rapid distribution of ICG and propofol. Examination of the 
propofol-concentration time data revealed that the peak arterial blood propofol 
concentration, with an average of 88 ± 17 µg.ml-1, profoundly exceeded that 
generally considered sufficient for surgical anesthesia (EC50 for loss of 





vascular compartment. The pharmacokinetic parameters of ICG are displayed 
in Table 1. The cardiac output in these healthy volunteers was close to  
7 L.min-1, equivalent to the sum of clearances of ICG. Furthermore, ICG 
elimination clearance was 1.19 L.min-1, smaller but close to the assumed 




The concentration-time data for ICG were modeled by the classic recirculatory 
model for the central circulation as discussed in chapter 2 of this thesis, with 
the addition of a venous lag time (Tlag) to correct for the delay of the drug 
transfer from the venous injection point to the right atrium. The parameters 
determined for ICG are represented in table 1. All parameters were distributed 
normally or lognormally. Parameters that were transformed back from 
logtransformation were VND-s, VSS, MTTC and MTTND-f. The model for the central 
compartment is represented in figure 2. 
 
For the modeling of the propofol concentration-time data, the recirculatory 
model that provided the best fit was selected following visual inspection and 
application of the Akaike criterion. The resulting recirculatory model consisted 
of two parallel tanks-in-series representing the central compartment including 
the lungs. The propofol concentration-time data before recirculation of propofol 
was observed, were analyzed separately using Erlang functions. This 
procedure is similar as is described for the modeling of the central 
compartment for ICG. The cardiac output and venous lag time were fixed 
according to the ICG model for each patient. No elimination from the pulmonary 
compartment could be determined. As a consequence, the pulmonary volume 
acted as a distribution volume and was determined as the difference in 
volumes of the central compartments determined for ICG and propofol. The 
peripheral part of the model consists of two parallel non-distributive pathways, 
a slow (ND-s) and a fast one (ND-f), defined by their volumes and clearances, 
and is completed by a peripheral distributive tissue compartment as can be 
seen in figure 3. 
 
The non-distributive compartments represent the part of the intravascular 
compartment outside the thorax and may represent vascular beds like the great 
vessels and the splanchnic vascular bed. The ratio between the fast and the 
slow intravascular pathway was kept equal for the ICG and the propofol model. 
The parameters for the recirculatory propofol model are presented in table 1 as 
well. All parameters were distributed normally or lognormally (ClND-f). The 

















parameter ClND-f was transformed back after logtransformation. The individual 
fits for the ICG and propofol concentration-time curves for the 10 patients show 
that the predicted ICG and propofol concentrations very closely correspond to 
those actually measured (Figure 4). Linear regression analysis showed good 
correlation between the measured and predicted blood propofol concentrations 
(R2 = 0.959; p<0.001, Figure 5). 
 
 
Figure 3 Representation of the recirculatory model used to fit the propofol 
concentration data. The intravascular compartment as described for ICG in figure 1 is 
extended with a peripheral tissue compartment VT. The ratio between the flows (ClND-f 
and ClND-s) to the non-distributive compartments VND-f and VND-s is kept equal to that 
determined for ICG. The total of all clearances equals the cardiac output. 
 
 
The propofol concentrations predicted by the pharmacokinetic models as 
described by Marsh23 and Schnider24, based on the simulated administration of 
a bolus propofol dose, are represented in figure 6. Plasma concentrations were 
simulated for the average bolus administered to a female patient with the 
average characteristics from our study population. The simulated plasma 
concentration curves are plotted against all plasma concentrations determined 
in our study. The curve constructed from the recirculatory pharmacokinetic 





blood propofol concentrations detected in our study by rapid sampling were 
almost 10 times higher as predicted by the Marsh model and twice as high as 
predicted by the Schnider model. 
 
 
Table 1 Pharmacokinetic parameters found for the ICG and propofol model, stating 
volumes (V) in L, clearances (Cl) in L.min-1 and mean transit times (MTT) in min for the 
central (C), non-distributive fast (ND-f), non-distributive slow (ND-s), tissue (T) and 
pulmonary (P) compartment, as well as the steady state volume (VSS) and the 
elimination clearance (ClEL) and cumulative clearance (∑Cl), which equals the cardiac 
output. Tlag represents the venous lag time. At the bottom row the lung retention in 
represented in %. Parameters are stated as mean with their standard error of the 
mean (SEM). 
 
 ICG propofol 
parameter mean SEM mean SEM 
VC 1.71 0.20 2.31 0.17 
VND-f 0.88 0.09 0.28 0.07 
VND-s 1.68 0.18 0.22 0.05 
VP   0.60 0.11 
VT   9.90 1.39 
VSS 4.22 0.35 12.71 1.41 
ClEL 1.19 0.11 3.38 0.23 
ClND-f 4.67 0.52 0.89 0.14 
ClND-s 1.12 0.15 0.25 0.05 
ClT   2.33 0.21 
∑Cl 6.98 0.47 6.98 0.47 
MTTC 0.24 0.03 0.34 0.03 
MTTND-f 0.19 0.03 0.30 0.05 
MTTND-s 1.78 0.26 0.93 0.11 
MTTT   4.29 0.54 
Tlag 0.13 0.02 0.08 0.02 
lungretention(%)   25.68 2.06 
 





Figure 4 Individual fits of the blood concentration data of Indocyanine Green (●) and 
propofol(Δ) in each patient. On the horizontal axis the time in min, on the vertical left 







Figure 5 Correlation of the measured versus predicted data for propofol. The 
regression formula is prop predicted= -424.7 + (1.112 * prop measured). The R2 





We studied the recirculatory pharmacokinetics of propofol with the aims to: 
 
1. Closely evaluate the early-phase concentration-time relationship of 
propofol during induction of anesthesia.  
2. To determine the role of the lung in the clearance and distribution of 
propofol.  
3. To compare the predictive accuracy of a recirculatory propofol 
pharmacokinetic model with compartmental models from the literature. 
 
We conclude that propofol, after bolus administration, exhibits blood 
concentrations that profoundly exceed those related to the hypnotic effect 
reflecting its poor initial mixing. We conclude that propofol shows no clinical 
relevant clearance from the lung. Lastly, we demonstrate that compartmental 
models, now widely used in anesthetic practice in target controlled infusion 




pumps, significantly underestimate the actual blood propofol concentration in 
the first minutes after induction of anesthesia. 
 
Figure 6 Simulations of the concentration-time curves of propofol after administration 
of an intravenous bolus of 201 mg to a female of 42 yrs, weight 67 kg and height 
1.72 m (averages in our study population) based on different pharmacokinetic models. 
The open circles represent all propofol blood samples in our study. The dotted curve is 
a simulation based on pharmacokinetics from the Marsh23 model; the propofol 
concentrations are underestimated in the peak and overestimated in the elimination 
phase. The striped curve is a simulation based on the pharmacokinetic model by 
Schnider24, which performs better, but still underestimates peak concentrations and 
those in the elimination phase. The solid line represents the simulation based on our 
average pharmacokinetic parameters from the recirculatory model. 
 
 
This recirculatory model compared to existing model. 
So far, the only recirculatory pharmacokinetic model for propofol in humans 
available was that by Upton et al.26, who gathered data from various sources to 
describe and model the distribution and elimination of propofol. Although we 
acknowledge the uniqueness of this model, various assumptions and estimates 
were necessary to develop this model that was accomplished after combining 





based on the available data but some parameters had to be estimated based 
on “known physiology”. In addition to the uncertainty involved with combining 
data from various sources, also the results presented by Upton, though very 
worthy form a physiological point of view, offer little clues to be implemented 
directly and associated to the clinical dose-concentration-effect relationship of 
propofol. Because, apart from Upton et al., only animal data were available on 
the recirculatory pharmacokinetics of propofol we studied the recirculatory 
pharmacokinetics in humans. 
 
Modeling of the pulmonary compartment 
The role of the lungs in the early phase of mixing and distribution of propofol 
into deeper tissue compartments remained yet not fully understood. Consensus 
exists in that the liver is the main organ of biotransformation and elimination of 
propofol, partly due to its high extraction ratio of up to 0.9. However, during the 
anhepatic phase in liver transplantations, extrahepatic clearance of propofol 
has been demonstrated. Also total body clearance exceeds the hepatic blood 
flow. To explore the role of the lung, recirculatory modeling of our data for 
propofol was initiated in analogy to the model described by Kuipers et al.17 
regarding the propofol recirculatory pharmacokinetics in sheep. In the sheep 
model pulmonary uptake was modeled by a distribution compartment placed in 
series with the tanks-in-series. For the description of lung uptake in our patients 
the addition of a distribution compartment, either parallel or in series, did not 
result in an adequate description of the concentration time curves for propofol. 
Yet, these curves of propofol and ICG were different, indicating a delay of 
propofol in the lungs. Pulmonary elimination could not be discerned from 
distribution or central elimination. Therefore a model for propofol was 
constructed in which pulmonary distribution was described by tanks-in-series 
only (Figure 1) to indicate a delay in the appearance of drug molecules at the 
effluent side of the organ. This delay is inhomogeneous compared to a fixed 
delay (expressed in sec). The pulmonary volume was determined as the 
difference between the combined volumes of the fast and slow central 
compartments for ICG and propofol.19 Also the mean transit times for ICG and 
propofol through the central compartment differed. 
 
The pulmonary first-pass uptake of propofol in our patients of 25.7 ± 6.5% is in 
agreement with the 28% reported earlier by He et al.27, however small 
compared to other intravenous drugs used in anesthesia, such as fentanyl, 
sufentanil or other basic amines.28 Despite the fact that propofol is highly 
lipophilic, the first pass lung uptake is relatively low. To be retained in the lungs, 
the drug in the lung tissue must be bound or otherwise hindered in the back 




release to the blood. One mechanism that may be involved in this, is that the 
drug is ionized. This mechanism probably plays a significant role for basic 
amines, in which cellular depots possibly play a role.29,30 Despite the fact that 
propofol is highly lipophilic, its pKa of 11 makes it more ionized than the basic 
amines, resulting in less retention in the lungs. That propofol can penetrate in 
due time in deeper compartments has been shown by Grossherr and co-
workers, who could detect propofol in epithelial line fluid.31 
 
Propofol lung uptake has been described in cats32, sheep17 and goats and 
pigs.33 Pulmonary uptake and more importantly clearance is disputed in 
humans.6,27,34 The lungs have been viewed as a possible site of clearance 
because propofol is detectable in exhaled air.9-11,13 Yet, the quantities exhaled 
by the lungs are expressed in parts per billion that are detected by very 
sensitive equipment. These quantities multiplied by the exhaled minute volume 
embody a very small amount compared to the quantities delivered by the 
venous blood through the cardiac output. In mechanically ventilated patients 
undergoing cardiac surgery, Grossherr and coworkers 12 measured 2.8 and 
22.5 ppb in exhaled air while the concurrent blood concentrations were 0.3 and 
3.3 µg/ml. From these and our data we conclude that propofol clearance by 
exhaling air is clinically insignificant. We assume that propofol is bound to the 
vascular tissues (endothelial lining) but that propofol does not transfer to “deep” 
compartments in the lungs. This would explain that a distribution compartment 
cannot be fitted and that propofol is better described using a dispersion model 
(tanks-in-series). We suspect that other sites of extrahepatic clearance are 
more important than the lungs and especially the kidneys are good candidates. 
Renal excretion of propofol and its metabolites has been demonstrated with a 
high renal extraction ratio of 0.6 to 0.73,4, leading to a renal clearance of almost 
up to 30% of the total body clearance. 
 
This recirculatory model compared to compartmental models 
The comparison of the predicted propofol concentrations based on the 
recirculatory pharmacokinetic model, with those predicted as based on the 
compartmental models by Marsh and Schnider, revealed a significant 
underestimation of the peak concentrations and an overestimation of the 
plasma concentration around the time of recirculation by compartmental 
models, as seen in figure 6. The fact that standard compartmental models 
poorly predict early-phase kinetics has been recognized before.19,35 Recently, 
an adaptation of a compartmental model by inclusion of a lag time and transit 
elements was introduced by Masui et al.36 Although this model performed 





remained. These misrepresentations may have clinical implications indeed. 
Underestimation of the propofol blood concentration may result in unnecessary 
overdosing of propofol and aggravated hemodynamic depression when 
propofol is administered by TCI based on compartmental pharmacokinetic 
models. On the other hand can an overestimation of the propofol blood 
concentration lead to insufficient sedation and increase the chance of 
awareness of the patient. 
 
In conclusion, we successfully described the pharmacokinetics of propofol by 
recirculatory modeling. After bolus administration, propofol exhibits blood 
concentrations that greatly exceed those related to hypnotic effect, reflecting its 
poor initial mixing. We conclude that propofol shows no clinical relevant 
clearance from the lung. Lastly, we demonstrated that compartmental models, 
now widely used in anesthetic practice in target controlled infusion pumps, 
significantly underestimate the actual blood propofol concentration in the first 
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Induction of anesthesia with an intravenous hypnotic agent like propofol can be 
achieved by administration of a manual bolus followed by a continuous 
infusion, with an infusion rate based on (lean) body weight, age and/or sex, or 
by using a computer controlled infusions systems for Target Controlled Infusion 
(TCI). In everyday practice a large interindividual variability in the induction 
phase can be observed, with variation in time to loss of consciousness, depth 
of sedation, and incidence and magnitude of respiratory and hemodynamic  
side effects, as has been reviewed in the Cochrane review by Leslie et al.1  
This variation is explained by the interindividual variability in pharmacokinetics 
and pharmacodynamics within the population. The origin of variability lies        
in the influence of age, weight, body composition, gender, comorbidities, 
hemodynamic variability like cardiac output, but also pharmacogenomics.2 
During induction or maintenance of anesthesia, interaction with co-
administered drugs like opioids, is evident.3,4 Opioids increase the blood 
concentration of co-administered hypnotic agents and shift the dose-reponse 
relationship of hypnotic agents to the left via pharmacodynamic interaction.5,6 
 
With the introduction of PK-PD modeling by Sheiner and colleagues7, the 
concept of the effect-site has been introduced: a virtual compartment that is 
coupled to the intravascular compartment via the transfer constant ke0 since the 
effect compartment has no apparent volume. Conventional 3-compartment 
models generally underpredict the intravascular drug concentration following a 
bolus induction dose of fast acting drugs like propofol see also chapter 2. In the 
study on early-phase pharmacokinetics of propofol described in chapter 6 of 
this thesis, we presented a recirculatory pharmacokinetic model for propofol in 
humans. In that study we simulated the blood concentration-time curve of a 
propofol bolus dose of 3 mg/kg as based on 2 pharmacokinetic parameter sets 
that are implemented in the commercially available TCI systems for propofol: 
the parameter set of Marsh8 in the Diprifusor™ by AstraZeneca and the 
parameter set of Schnider9 in the Orchestra Base Primea™ by Fresenius Kabi. 
Through these simulations we demonstrated that the peak concentrations of 
propofol after the administration of a bolus of 3 mg.kg-1 could be well predicted 
by our recirculatory model, but were significantly underestimated by the other 
PK sets. 
 
During TCI both the effect-site concentration may be targeted, as well as the 
plasma site, depending on the PK-PD parameter sets available in the device. 





implemented effect site equilibration half-life is determined in the same 
population as the pharmacokinetic parameters are, as is the case for the 
Schnider effect site TCI (ke0 of 0.456 min
-1).9 This is not the case for the Marsh-
effect site TCI (ke0 of 0.26 min
-1)10, as is used in the Diprifusor™. In targeting 
the effect-site concentration, the pharmacodynamic variability is superimposed 
upon the pharmacokinetic variability and/or inaccuracy of the pharmacokinetic 
model. 
 
Knowing the poor prediction of the blood drug concentration by compartmental 
models in the early-phase after a bolus drug dosing, we explored the effect-site 
equilibration of propofol as based on recirculatory modeling with the bispectral 
index (BIS) as effect parameter and compared this to the effect-site 
equilibration of propofol as described by the compartmental models of Marsh 





Patients and Procedures 
The concentration-time-effect data used in this study were gathered during the 
study on early-phase pharmacokinetics of propofol as described in chapter 6. In 
this study, with approval of the Medical Ethics Committee of the Leiden 
University Medical Centre and written informed consent, the propofol dose-
concentration-effect data of 10 patients, ASA physical status I or II scheduled 
for elective surgery, were studied. Based on highly frequent arterial blood 
sampling during the first minutes after administration of an iv bolus of 3 mg.kg-1 
of propofol, we developed a recirculatory model, using indocyanine green as a 
marker for the intravascular compartment. 
 
Data collection 
Prior to the study a cannula was inserted in a large vein in the fossa cubiti for 
fluid and drug administration. The radial artery was cannulated for the collection 
of arterial blood samples and hemodynamic monitoring. At every heart beat the 
arterial systolic blood pressure (SBP), diastolic blood pressure (DBP), mean 
arterial pressure, heart rate, cardiac output and stoke volume were gathered, 
provided the arterial cannula was not used for blood sampling. ECG monitoring 
was applied as well. Peripheral oxygen saturation and pulse rate were 
measured using a finger probe. Sedative data were gathered using the 
bispectral index (BIS) (A-2000, Aspect Medical Systems, USA); the raw and 




processed electroencephalogram (EEG) data were transferred to a laptop 
computer every second. Control blood samples were taken for the construction 
of reference aliquots. Before the start of each experiment, baseline 
measurements of the arterial blood pressure, heart rate (HR), cardiac output 
(CO) and BIS were recorded for at least 15 min. After 3 min of preoxygenation 
with 100% O2, each session started with the rapid intravenous administration of 
propofol 3 mg.kg-1, mixed with ICG 10 mg (Infracyanine®, Laboratoire SERB, 
France) as described before.11 The propofol/ICG bolus was immediately 
followed by a rapid bolus of 20 ml of NaCl 0.9%. A computer-controlled syringe 
pump combined with a fraction collector was programmed to draw 37 arterial 
blood samples in the first 2.5 min after propofol administration at 3 sec apart for 
the first 1.5 min, then at every 10 sec for the remaining min. Due to the 
construction of the sampling device, no mixing in the tubing could occur, as has 
been described before.11 Five more samples were drawn manually up to 
10 min after administration of the propofol bolus dose, at 3, 4, 5, 7.5 and 10 
min. During manual sampling, a waste sample was drawn first. The blood 
samples were collected in heparinized glass tubes and processed immediately 
by HPLC as described in chapter 6. The study ended when the patient showed 
clear signs of arousal, if the BIS reached 80 or after 10 minutes. 
 
Data processing 
BIS and raw EEG data were transferred from the A-2000 monitor to a laptop 
and imported into a spreadsheet program (Excel 2000, Microsoft Corporation, 
Seattle, U.S.A.). The A-2000 calculated the BIS and other processed EEG 
variables based on artefact-free epochs of data, where each epoch is 
2 seconds. Each calculated value was based on an average of the last n 




A recirculatory PK model was constructed for propofol, using the indicator ICG 
to estimate the intravascular compartment, as is described in chapter 6. 
A recirculatory model consisting of central and non-distributive delay 
compartments for the intravascular compartment, combined with a single tissue 
compartment and a venous lag-time, described the propofol blood 
concentrations best. The parameters found for propofol included a steady-state 
volume of 12.7 ± 1.4 L, a pulmonary volume of 0.6 ± 0.1 L, a tissue volume of 
9.9 ± 1.4 L, an elimination clearance of 3.4 ± 0.2 L.min-1 and a venous lag time 
of 0.08 ± 0.02 min. The mean cardiac output was 7.0 ± 0.5 L.min-1. For the 






The relationship between the propofol blood concentrations and the hypnotic 
effect measured by BIS was analyzed by coupling an effect compartment to  
the pharmacokinetic model via a link parameter (Figure 1). As the effect 
compartment is assumed to have an infinitively small volume, the link 
parameter is reported as ke0.
7 This parameter is also reported as the 
equilibration half-time (t1/2ke0 = ln2/k). 
 
Figure 1 Representation of the recirculatory model used to fit the propofol 
concentration data. The pharmacokinetic recirculatory model for propofol in chapter 6 
is extended with an effect compartment. The effect compartment is coupled to the 
blood compartment via the first order rate constant ke0. 
 
 
The BIS data were transferred to the SAAM program (SAAM II, version 1.1.1, 
SAAM Institute, University of Washington, USA) and fitted to a sigmoid Emax 
model using the Hill equation, which is defined by Emax, slope gamma and the 
EC50  (the concentration at which 50% of the effect is achieved). Two types of 
the effect model were analyzed: the classic form, which is called model 1 and 
an alternative model in which a pharmacodynamic lag time Tlag-PD was added to 
partially account for the delay in onset of the effect. This is defined as model 2 
and is comparable to the pharmacodynamic modeling of the effect on BIS of 























 Using the pharmacodynamic parameter sets determined for model 1 and 2 as 
described above, the effect site concentration was calculated. The effect site 
concentration was also simulated for the pharmacokinetic parameter sets 
described by Schnider and Marsh, combined with their respective ke0 of 0.456 
and 0.26 min-1, as implemented in TCI systems for effect-site targeted infusion 
of propofol. The input for the simulation was a bolus of 201 mg of propofol 
administered to a female weighing 67 kg and with a length of 1.72 m, the 
average of our study population. 
 
Statistical Analysis 
Descriptive statistics were generated by the SPSS statistical package (SPSS, 
version 17). Parameters were tested for normality using the Kolmogorov-
Smirnov test. Parameters that were not normally distributed were tested for 
normal distribution after log transformation. If log transformation then revealed 
a normal distribution, the mean and standard error of the mean (SEM) were 
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where μ and σ represent the mean and SD in the log transformed dataset. 
Linear regression analysis was performed using the same statistical package. 
Means of the parameters between groups and the squared residuals of the 
measured versus the predicted effect data were tested for difference using the 
Paired Samples T-Test. Difference in goodness of fit between model 1 and 2 
for each patient was tested using the F-test. Statistical significance was 
assumed at p<0.05. Data are reported as mean ± standard deviation (SD), 












The 10 patients included were 2 males and 8 females, who were aged 
42.2 ± 8.7 yr, weighed 67.1 ± 11.8 kg, were 1.72 ± 0.1 m with a body mass 
index of 22.5 ± 2.2 kg.m-2. 
 
The induction of anesthesia with the intravenous bolus dose of propofol 
(3 mg.kg-1) resulted in a rapid loss of consciousness in all patients with a lowest 
BIS of 24 ± 9, measured at 75 (60-115) sec (median and range) after the 
intravenous administration of propofol. All patients had to be ventilated by mask 
to maintain oxygenation. When the blood propofol concentration decreased 
after the bolus dose administration and BIS levels increased again to a mean 
BIS of 72 ± 9, the data collection was terminated to assure that patients 
remained unconscious. The study was then terminated and anesthesia 
continued with propofol, remifentanil and atracurium and the trachea was 
intubated. The patients then were ready for their scheduled surgical procedure. 
The study was completed without any adverse event. No patients reported any 
signs of awareness. 
 
PK-PD model 
Via a data transfer protocol the raw and processed EEG variables were 
registered from the A-2000 monitor. A BIS value was generated every second. 
In order to capture the rapid change in levels of hypnosis, no averaging was 
performed on the generated BIS data. The data sets therefore contained    
270 - 600 data points for the BIS effect measurement. Firstly, the BIS data 
were analyzed using a classic sigmoid Emax model, coupled to the blood 
concentration of propofol via ke0 (Figure 1). This was defined as model 1. 
Visual inspection of the BIS data over time revealed a varying time to onset of 
the effect (BIS drop), after which in most patients the BIS decreased rapidly, to 
consequently regain higher BIS values in a slower manner. This effect pattern 
was only poorly reflected by the parameters ke0 and γ in the classical model 1. 
To improve the quality of fit of model 1 a modification was made to the 
pharmacodynamic model by introducing a pharmacodynamic lag time Tlag-PD. 
This improved the fit of the PD data and was defined as model 2. The 
parameters determined by fitting model 1 and model 2 are represented in   
table 1. The parameters determined by model 1 showed a normal distribution. 
The parameters determined by model 2 showed a normal or lognormal 




(EC50 and ke0) distribution. All parameters differed significantly between the 
models according to the Paired Samples T-test (p<0.05). 
 
Table 1 Parameters describing the pharmacodynamics of propofol based on 
recirculatory pharmacokinetics, determined by two different pharmacodynamic models. 
In model 1 a standard sigmoid Emax model is coupled to the blood concentration via a 
single transfer constant ke0. In model 2 the sigmoid Emax model is linked via a 
pharmacodynamic lag time combined with the transfer constant ke0. 
 
Parameter Model 1 Model 2 
 Mean SEM Mean SEM 
EC50 (µg.ml
-1) 2.79 0.12 3.82 0.35 
Emax 97.7 0.5 96.5 0.5 
gamma 14.67 2.71 3.69 0.75 
t1/2ke0 (min) 7.33 0.56 3.82 0.65 




For an illustrative patient the PK-PD model fitted to the BIS data using model 1 
(panel A) or model 2 (panel B) is presented in figure 2. Improvement of fit of the 
induction phase with model 2, when a pharmacological lag time was 
introduced, is clearly visible. 
 
Linear regression analysis of the predicted versus measured effect data 
showed a better correlation for model 2 than for model 1 (R2 of 0.940 vs 0.883, 
both p<0.0001, Figure 3). The residuals of the measured versus predicted 
effect for all data points in all patients are represented in time in figure 4. The 
squared residuals of model 1 differed significantly from those of model 2 
(p<0.001), as determined by the Paired T-test. The F test provided further 
evidence that model 2 fitted the data significantly better than model 1 
(p<0.0001). The fitted curve based on the pharmacodynamic parameters for 
model 2 in reference to the measured BIS curves of all patients is represented 







Figure 2 Fit of the pharmacodynamic data of propofol in a representative patient, 
using two PK-PD models: in panel A the effect is directly coupled to the central blood 
compartment via ke0 (R
2=0.84), in panel B a pharmacodynamic lag time (Tlag-PD) is 
added to the model (R2=0.90). The F test showed that model 2 fitted the data better 
than model 1 (p<0.0001). 






Figure 3 Measured versus predicted BIS effect data, fitted with model 1 (R2=0.883) 







Figure 4 Residuals of the measured versus predicted BIS values for all datasets, fitted 
with model 1 (classical model) and model 2 (model including a pharmacodynamic lag 
time). The squared residuals differed significantly for the 2 models (p<0.05). 





Figure 5 The fitted pharmacodynamic model for BIS based on the parameters derived 
with model 2, including a pharmacological lag time (thick solid line) amid the measured 





Compartmental modeling poorly describes propofol concentrations during the 
initial mixing phase and thus may misjudge the blood-effect site disequilibrium. 
We explored the effect-site equilibration of an induction bolus of propofol by 
recirculatory pharmacokinetic modeling combined with BIS as effect parameter, 
and compared this to the ke0 as based on compartmental modeling. We 
successfully defined the recirculatory equilibration constant (ke0) for the effect 
of propofol on BIS in 2 ways. The ke0 determined by the first, classic 
recirculatory PK-PD model was about 50% of the ke0 reported in literature as 
determined by compartmental PK-PD modeling. This is in analogy with similar 
recirculatory-compartmental ke0 comparisons e.g. for rocuronium (0.13 versus 
0.24).13 The equilibration half-life t1/2ke0 determined by the second model, in 
which a variable pharmacodynamic lag time was included, generated a better 
fit of the median time to peak effect that was observed at 1.25 min. 
Compartmental pharmacokinetic models underestimate the blood propofol 





pharmacokinetic model this PK-underestimation is compensated for by a 
consecutive overestimation of the effect-site equilibration time. With this notice 
we demonstrate that a reported ke0 can only be interpreted in context with its 
PK-PD model. 
 
Limitations of the study 
Pharmacodynamic modeling of the sedative effect of propofol has been 
performed using multiple effect parameters like the mid-latency auditory evoked 
potentials14,  spectral edge frequency10, bispectral index score15, CUP9 and 
permutation entropy16, which are all EEG derived effect parameters. These 
effect parameters are derived, scaled and averaged in different ways, often 
undisclosed to the public. Albeit the fact that BIS is subject to a moving average 
(which can be adjusted from 30 to 15 sec on the monitor) and therefore shows 
an implicit delay, the method is widely available and has been incorporated into 
the standard OR equipment. Uncertainty on the mathematics by which the BIS 
is calculated did not outweigh the practical benefits of the BIS as effect 
parameter. By downloading the raw EEG data from the A-2000 monitor, we 
attempted to construct the fast reacting parameter permutation entropy. 
However, this was hampered by the occurrence of burst suppression after 
administration of the induction bolus of 3 mg.kg-1 of propofol. The way that BIS 
handles artifacts (which can be any rapid change in the signal) by maintaining 
its former level, combined with the fact that excitation which is observed in the 
EEG at the start of induction and cannot be reflected by BIS, may account for 
the delay we observed in our effect measurements.17 This phenomenon has 
been solved before by constructing a biphasic18 or 2-compartment effect model 
for EEG.19 Addition of a fixed lag time of 0.1 min has been described by Struys 
et al.12 To deal with comparable problems, Kazama and colleagues did not 
start fitting the ke0 until 1.25 min after adjusting the targeted propofol 
concentration in their TCI system and measuring EEG with the A-1000.20 
 
In our model we chose to introduce a variable pharmacodynamic lag time to 
account for delay in effect on mathematical grounds. However, considering the 
high blood peak concentrations we detected by rapid sampling, it may also 
reflect other phenomena like the transport through the microcirculation21,22 and 
diffusion kinetics23 that influence the equilibration ratio from the blood to the 
effect compartment. The Tlag-PD showed correlation with the cardiac output 
(R2=0.524, p<0.02). 
 
The number of patients enrolled in this study is relatively small. However, the 
vast amount of data generated by the high sampling frequency of blood 




concentrations as well as effect measurements, allowed for accurate fitting and 
less need for interpolation. The variability on the pharmacodynamic parameters 
is therefore not due to a large variability in the pharmacokinetics. 
 
The real ke0? 
The findings in this study once more demonstrate that no such parameter as 
the real ke0 for propofol exists. Up to now a number of studies have been 
performed, generating various values for the ke0 (and its equilibration halftime) 
for propofol. Billard et al.  reported a ke0 of 0.20 (t1/2ke0: 3.5 min);
10 Schnider et 
al. reported a  ke0 of  0.456 (t1/2ke0: 1.51 min)
9 and Struys et al. of 1.21 (t1/2ke0: 
0.57 min)24 and later of 0.58 (t1/2ke0: 1.2 min) for a bolus and 0.32 (t1/2ke0: 2.2)
12 
for infusion based on BIS, whereas a ke0 of 0.26 (t1/2ke0: 2.6 min) based on 
auditory evoked potentials is incorporated in the Diprifusor (preliminary results 
presented by M. White).25 Kazama et al. compared 4 age groups, receiving a 
step-up schedule of propofol TCI. For each age group a different ke0 could be 
determined, even with or without taking EEG activation into account. Values for 
t1/2ke0 varied between 2.29 and 4.33 min.
20 The implications of combining 
different PK data sets with various ke0 values is clearly described by Glen.
25 
Misinterpretation may lead to underdosing with the risk of awareness, or 
overdosing with the possibility of eliciting side effects like hemodynamic and 
cardiac depression. To illustrate this we simulated the calculated effect-site 
concentration, based on our recirculatory pharmacokinetic model that is 
presented in chapter 6. We compared this to the calculated effect-site 
concentrations produced by the PK-PD model described by Schnider and by 
Marsh (Figure 6). 
 
Due to lack of information on the complete pharmacodynamic model on which 
the ke0 of Schnider (0.456) and Marsh (0.26) are based, we could not simulate 
the BIS effect which would be expected at the calculated effect site 
concentration. Both the Marsh and Schnider models are implemented in 
commercially available TCI systems. 
 
The simulations of the effect-site concentration show the influence of the 
parameter sets on the calculated effect-site concentration and its time-course. 
Interpretation of the effect-site concentration involves knowledge of the EC50 
which determines the desired target concentration. Furthermore, the ke0 is 
influenced by the mode of administration, i.e. bolus or infusion12. In our study 
ke0 showed correlation with cardiac output as well (R








Figure 6 Simulations of the effect-site concentrations calculated from the PK-PD 
models described by Marsh25, Schnider9 and model 2 presented in this study. Note the 
high Ce from the Schnider model and the delay in time to peak effect (max Ce) with 




We explored the effect-site equilibration of an induction bolus of propofol by 
recirculatory pharmacokinetic modeling combined with BIS as effect parameter, 
and compared this to the ke0 as based on compartmental modeling. We 
successfully defined the recirculatory equilibration constant (ke0) for the effect 
of propofol on BIS. The classically determined ke0 was about 50% of the ke0 
reported in literature as determined by compartmental PK-PD modeling. Effect 
data were best fitted after inclusion of a variable pharmacodynamic lag time.  
 
Compartmental pharmacokinetic models underestimate the blood propofol 
concentration after induction of anesthesia. When modeling the effect in 
relation to a compartmental pharmacokinetic model this PK-underestimation is 
compensated for by a consecutive PD-overestimation of the effect-site 
equilibration constant (ke0). With this we draw attention to the fact that a ke0 
may only be implemented within the context of the pharmacokinetic model used 
and the effect parameter studied. 
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The pharmacology of the induction of anesthesia is still poorly understood. As a 
consequence, the onset of anesthesia is often associated with hemodynamic 
and respiratory depression resulting from a relative anesthetic overdose, while 
at other times patients receive an insufficient dose and suffer from inadequate 
analgesia or awareness. The pharmacology of the induction of anesthesia is 
regularly described using compartmental modeling, although this method is 
generally known to predict drug concentrations during induction inaccurately. 
This inaccuracy, as well as the clinical importance of proper induction dosing, 
elicited the studies in this thesis. Our aim was to better describe the early 
phase pharmacokinetics and pharmacodynamics of anesthetic agents through 
recirculatory modeling. Because indocyanine green (ICG) plays an important 
role in recirculatory modeling, the first part of this thesis deals with the analysis 
and modeling of ICG in blood. 
 
In chapter 2 a general overview of the various methods of pharmacokinetic 
modeling is given. The pros and cons of compartmental and more 
physiologically-based analytical methods of defining the dose-concentration-
effect relationship of anesthetic agents, are described. The recirculatory model 
described by Kuipers et al. for the muscle relaxant rocuronium, using ICG as 
intravascular marker, is discussed in detail. 
 
In chapter 3 we evaluated the accuracy of the noninvasive transcutaneous 
measurement of ICG by the DDG-2001. Two different probes were used to 
determine transcutaneously the concentration of ICG in blood and the derived 
hemodynamic parameters cardiac output, central blood volume and total blood 
volume. These measurements were compared to the simultaneous 
measurements of ICG in arterial blood, and the derived hemodynamic 
parameters based on arterial measurements, acquired by rapid sampling. The 
results of this study seriously question the reliability of the noninvasive 
measurement of cardiac output and central blood volume in the individual 
patient as measured by pulse-dye densitometry with the DDG-2001. Both the 
finger and nose probe proved equally unreliable. The overall conclusion of this 
study is that, although total blood volume is measured relatively better, the 
DDG-2001 is not accurate enough for noninvasive cardiac output measurement 
to be clinically useful in hemodynamic monitoring. 
 
In chapter 4 we studied the accuracy of the noninvasive measurement of the 





measurement of ICG, in the population described in chapter 3. ICG-PDR is 
used clinically as a measure of hepatic failure, for example in patients directly 
after liver transplantation. As data on transcutaneously measured ICG-PDR in 
patients without liver failure is scarce, this was explored. Respectively, the 
Pulse Dye Densitometry (PDD) finger and nose probe showed a relative bias of 
12% and -23%, compared to arterial ICG measurements. The mean ICG-PDR 
was 23.1 %.min-1, comparable to previously published data. However, the ICG-
PDR variability in this healthy population proved much larger than previously 
described (95% CI: 7.4-38.8%.min-1). Patients with an ICG-PDR of 8 %.min-1 
may thus exhibit normal liver function in contrast to the former cited cut off 
value of 18 %.min-1, indicating liver failure. Further evaluation of ICG-PDR in 
the healthy population may improve our insight in the value of this parameter in 
patients suffering from hepatic failure or post liver transplantation. 
 
In chapter 5 we evaluated a circulatory pharmacokinetic model for rocuronium, 
based on intravascular and diffusion kinetics. The data upon which this model 
is based were the same as those described in chapter 2 by Kuipers et al. It was 
not the goal of this study to improve the fit of the rocuronium data relative to 
that already obtained, but rather to better understand the role of vascular 
mixing (transit time dispersion) and interstitial diffusion. The study 
demonstrated the applicability of the transit time dispersion based model of 
vascular mixing and the diffusional tissue distribution model in clinical 
pharmacokinetics. It accounts for the importance of the roles of circulatory 
mixing and diffusion into the interstitial fluid in determining the distribution 
kinetics of rocuronium, and thus sheds new light on our understanding of 
underlying transport physiology. The importance of flow is stressed by the 
significant correlation between cardiac output and cardiopulmonary volume 
described in this study and by the fact that systemic transit time dispersion 
decreased with increasing cardiac output. Future applications may include 
other drugs or reveal the effect of disease states on drug distribution. 
 
In chapter 6 a recirculatory pharmacokinetic model for propofol in humans is 
presented. The model describes the distribution, recirculation and elimination of 
propofol after the administration of an induction bolus dose, based on ICG 
pharmacokinetics. The role of the lung in the distribution and elimination of 
propofol is discussed. We successfully described the pharmacokinetics of 
propofol by recirculatory modeling. After bolus administration, propofol exhibits 
blood concentrations that exceed by 10-30 fold those related to hypnotic effect, 
reflecting its poor initial mixing. We conclude that propofol shows no clinically 
relevant clearance from the lung. Lastly, through computer simulation we 
demonstrated that compartmental models, now widely used in anesthetic 




practice in target controlled infusion pumps, significantly underestimate the 
actual blood propofol concentration in the first minutes after induction of 
anesthesia. 
 
In chapter 7 the recirculatory pharmacokinetic model for propofol was 
implemented in a pharmacokinetic-pharmacodynamic model for propofol. The 
effect was measured by the bispectral index score (BIS). We explored the 
effect-site equilibration of an induction bolus of propofol by recirculatory 
pharmacokinetic modeling combined with BIS as effect parameter, and 
compared this to the ke0 as based on compartmental modeling. We 
successfully defined the recirculatory equilibration constant (ke0) for the effect 
of propofol on BIS. The ke0 determined by the classically based, recirculatory 
PK-PD model was about 50% of the ke0 reported in literature as determined by 
compartmental PK-PD modeling. However, effect data were best fitted after 
inclusion of a variable pharmacodynamic lag time of approximately 0.5 min. 
Compartmental pharmacokinetic models underestimate the blood propofol 
concentration after induction of anesthesia. When modeling the effect in 
relation to a compartmental pharmacokinetic model this PK-underestimation is 
compensated for by a consecutive PD-overestimation of the effect-site 
equilibration constant (ke0). With this we draw attention to the fact that a ke0 
may only be implemented within the context of the pharmacokinetic model used 
and the effect parameter studied. 
 
 
Conclusions and Future Perspectives 
 
Titration to effect is the most important action anesthesiologists use to assure 
adequacy of anesthesia and safeguard their patients from serious side effects. 
For a proper titration to effect the anesthesiologist takes into consideration the 
historical response to a given dose to estimate the response to a future dose. 
During induction of anesthesia the anesthesiologist is still unaware of the dose-
response relationship of the patient and titration is therefore impossible. As a 
result population PK-PD data are of great importance during induction of 
anesthesia. Because for many agents the knowledge of the covariates of 
influence on the induction dose-response relationship is lacking, many patients 
experience serious side effects during induction of anesthesia, often in the form 
of hemodynamic depression. 
 
In this thesis light is shed on the pharmacology of induction of anesthesia. The 





this thesis teach us that the modeling of the dose-concentration-effect relation 
is insufficiently described by compartmental modeling and improves by 
applying recirculatory PK-PD modeling. (Non)invasive ICG measurement is 
used extensively in recirculatory modeling but is less well suited for 
hemodynamic monitoring. 
 
We started this work with the idea that with the noninvasive measurement of 
ICG and the derived hemodynamic parameters like cardiac output, at the 
bedside before induction, we would be able to identify the relevant parameters 
of the recirculatory model of ICG and of the drug used for induction of 
anesthesia. This result has not been reached in this thesis and requires further 
study. Future research may aim at clarification of the influence of various 
covariates on the recirculatory PK-PD in the induction phase, the relationship 
between the high peak concentrations in blood after bolus administration and 
the hemodynamic depression, and at the influence of co-administered opioids 
or hypnotic agents used as premedication drugs on the dose-concentration-
effect relationship of propofol. Inclusion of subjects with differing physiology 
based on age, weight or illness, will extend the knowledge on the impact of 
recirculatory modeling in these patient groups. The need for a fast responding 
and predictive effect parameter to measure rapidly changing states of 
consciousness remains. With the application of sampling at high frequency of 
both blood and effect, new phenomena may be revealed which will necessitate 








































De farmacologie van de inductie van anesthesie, het in slaap maken, is nog 
steeds moeilijk te doorgronden. Dit heeft onder andere nog steeds tot gevolg 
dat de aanvang van anesthesie enerzijds veelal geassocieerd is met 
hemodynamische instabiliteit en ademhalingsdepressie ten gevolge van een 
relatieve overdosering van anesthetica, terwijl anderzijds patiënten door een 
ondermaatse dosering het slachtoffer kunnen worden van inadequate 
pijnstilling of het optreden van awareness. De farmacokinetiek van de inductie 
van anesthesie wordt veelal beschreven met behulp van compartimentele 
modellen, hoewel het bekend is dat via deze methode de 
geneesmiddelconcentratie tijdens de inductiefase onnauwkeurig wordt 
voorspeld. Deze onnauwkeurigheid, naast het klinische belang van het 
adequaat doseren tijdens de inductiefase, zijn de aanleiding geweest tot het 
opzetten van de onderzoeken beschreven in dit proefschrift. Het was ons doel 
de vroege fase farmacokinetiek en farmacodynamiek van anesthetica te 
beschrijven met behulp van een recirculatoir model. Aangezien de kleurstof 
indocyanine groen (ICG) een belangrijke rol speelt bij recirculatoir modelleren, 
zijn de eerste hoofdstukken van dit proefschrift gewijd aan de bepaling en het 
modelleren van ICG concentraties in bloed. 
 
In hoofdstuk 2 wordt een overzicht gegeven van de verschillende methoden 
van farmacokinetisch modelleren. De voors en tegens worden beschreven van 
compartimentele- en meer fysiologisch gestoelde analytische methoden voor 
het beschrijven van de dosis-concentratie-effect relatie van anesthetica. Het 
recirculatoire model zoals beschreven door Kuipers et al. voor de 
spierverslapper rocuronium, waarbij ICG is gebruikt als intravasculaire marker, 
wordt uitgebreid besproken. 
 
In hoofdstuk 3 wordt de nauwkeurigheid van de niet-invasieve transcutane 
meting van ICG met behulp van de DDG-2001 geëvalueerd. Twee 
verschillende detectoren zijn gebruikt om door de huid de concentratie van ICG 
in het bloed te meten en hieruit de hemodynamische parameters 
hartminuutvolume, centraal bloed volume en totaal bloed volume te berekenen. 
Deze transcutane metingen zijn vergeleken met metingen in simultaan 
afgenomen arteriële bloedmonsters. De hemodynamische parameters zijn ook 
vergeleken met de berekeningen, afgeleid uit hoog frequente arteriële 
bloedmonsters. De resultaten gevonden in dit onderzoek trekken de 
betrouwbaarheid van de niet-invasieve meting van het hartminuutvolume en 





individuele patiënt zoals uitgevoerd via pulse-dye-densitometrie met de DDG-
2001. Zowel de neus- als de vingerdetector bleken even onbetrouwbaar. De 
algemene conclusie van dit onderzoek is dat, hoewel de meting van het totale 
bloedvolume betere resultaten liet zien, de DDG-2001 niet nauwkeurig genoeg 
is in het niet-invasief meten van het hartminuutvolume, om klinisch toepasbaar 
te zijn als hemodynamische bewaking. 
 
In hoofdstuk 4 wordt het onderzoek gepresenteerd naar de nauwkeurigheid 
van de niet-invasieve meting van de indocyanine groen plasma verdwijnings 
ratio (ICG-PDR), vergeleken met deze meting in slagaderlijk bloed. Deze 
vergelijking is bestudeerd in dezelfde patiëntengroep als beschreven in 
hoofdstuk 3. ICG-PDR is klinisch in gebruik als maat voor leverfalen, 
bijvoorbeeld bij patiënten na levertransplantatie. Aangezien er weinig gegevens 
beschikbaar zijn betreffende de transcutane meting van ICG-PDR in patiënten 
zonder leverfalen, hebben wij hier nader onderzoek naar gedaan. De         
Pulse Dye Densitometrie (PDD) vinger- en neusdetector lieten een relatieve 
bias zien van respectievelijk 12% en -23%, wanneer vergeleken met metingen 
van ICG in arterieel bloed. De gemiddelde ICG-PDR was 23,1 %.min-1, 
vergelijkbaar met eerder gepubliceerde gegevens. Echter, de spreiding in   
deze gezonde populatie bleek veel groter te zijn dan eerder was beschreven      
(95% betrouwbaarheidsinterval: 7,4 – 38,8 %.min-1). Patiënten met een      
ICG-PDR van 8 %.min-1 kunnen dus een normale leverfunctie hebben, in 
tegenstelling tot de eerder beschreven onderwaarde van 18 %.min-1, welke 
leverfalen zou indiceren. Een verdere evaluatie van ICG-PDR in de gezonde 
populatie kan onze inzichten in de waarde van deze meting bij patiënten met 
leverfalen of na levertransplantatie vergroten. 
 
In hoofdstuk 5 wordt een circulatoir farmacokinetisch model voor rocuronium 
beschreven, dat gebaseerd is op intravasculaire– en diffusie kinetica. De 
gegevens waar dit model op is gebaseerd, zijn dezelfde als welke zijn gebruikt 
voor het model beschreven in hoofdstuk 2 door Kuipers et al. Het doel van 
deze studie was niet het verbeteren van de fit van de rocuronium data ten 
opzichte van het eerder beschreven model, maar om een beter inzicht te 
krijgen in de rol van menging in het vaatbed (transit tijd dispersie) en de rol van 
diffusie naar het interstitium. Dit onderzoek toonde aan dat het model, dat 
gebaseerd is op de transit tijd dispersie van intravasculaire menging en diffusie 
naar het interstitium, goed toepasbaar is op farmacokinetische data uit de 
klinische praktijk. Het geeft hiermee het belang weer van circulatoire mixing en 
diffusie naar de interstitiële vloeistof, bij het bepalen van de distributie kinetiek 
van rocuronium. Hiermee is ons inzicht in de fysiologie van geneesmiddelen 
transport toegenomen. De belangrijke rol van stroomsnelheid wordt benadrukt 




door de significante correlatie tussen hartminuutvolume en cardiopulmonale 
volumina beschreven in deze studie. Tevens neemt de systemische transit tijd 
dispersie af bij een toename van het hartminuutvolume. In de toekomst zal     
dit model toegepast kunnen worden op andere geneesmiddelen. Daarnaast 
kan het beter inzicht geven in de rol van ziekte op de verspreiding van 
geneesmiddelen in het lichaam. 
 
In hoofdstuk 6 wordt een recirculatoir farmacokinetisch model voor propofol in 
mensen gepresenteerd. Dit model beschrijft de verdeling, recirculatie en 
uitscheiding van propofol na het toedienen van een standaard bolus inductie 
dosis, gebaseerd op de farmacokinetiek van ICG. De rol van de long in de 
verdeling en uitscheiding van propofol wordt nader belicht. Op succesvolle 
wijze hebben wij de farmacokinetiek van propofol beschreven met behulp van 
een recirculatoir model. Na een bolus toediening van propofol worden 
concentraties gevonden die 10-30 keer de concentratie overtreffen, die 
gerelateerd is aan hypnotisch effect. Dit illustreert de slechte mixing in de 
initiële fase. Verder concluderen wij dat klaring van propofol door de long niet in 
klinische relevante mate aanwezig is. Tenslotte maken we door computer 
simulaties duidelijk dat compartimentele modellen de werkelijke concentratie 
van propofol in het bloed direct na de inductie van anesthesie, significant 
onderschatten. Dergelijke modellen worden in de klinische praktijk via doel 
gestuurde infusie pompen veelvuldig gebruikt. 
 
In hoofdstuk 7 is het recirculatoire farmacokinetische model voor propofol 
geïmplementeerd in een farmacokinetisch-farmacodynamisch (PK-PD) model 
voor propofol. Het effect van de anesthesie is gemeten met de bispectrale 
index score (BIS). Het bereiken van het evenwicht tussen de concentratie van 
propofol in het bloed en het effect compartiment, na het toedienen van een 
bolus propofol, is onderzocht door middel van het combineren van het 
recirculatoire farmacokinetische model voor propofol met BIS als effect 
parameter. De effect compartiment equilibratie constante ke0 is vergeleken met 
die, zoals bekend bij compartimentele modellen. Met succes hebben wij de 
recirculatoire equilibratie constante ke0 kunnen bepalen voor het effect van 
propofol op de BIS in twee verschillende modellen. De ke0 bepaald uit het 
klassiek gestoelde recirculatoire PK-PD model, was ongeveer 50% van de ke0 
zoals gerapporteerd in de literatuur, op basis van compartimentele modellen. 
De effect data konden echter het beste gefit worden na toevoeging van een 
variabele farmacodynamische vertragingstijd van ongeveer een halve minuut. 
Compartimentele farmacokinetische modellen onderschatten de concentraties 
van propofol in het bloed na de inductie van anesthesie. Tijdens het modelleren 





wordt de farmacokinetische onderschatting blijkbaar gecompenseerd door een 
daaropvolgende farmacodynamische overschatting in de effect compartiment 
equilibratie constante ke0. Hiermee benadrukken wij dat een ke0 altijd 
beschouwd moet worden in de context van het farmacokinetische model dat is 
gebruikt en de effect parameter die is gemeten. 
 
 
Conclusies en toekomstperspectieven 
 
Titreren op effect is de belangrijkste vaardigheid die anesthesiologen gebruiken 
om een adequate anesthesie te waarborgen en hun patiënten te behoeden 
voor ernstige bijwerkingen. Om goed te kunnen titreren op effect, is een 
eerdere reactie op een toegediende dosis maatgevend voor de grootte van de 
volgende dosis. Tijdens de inductie van anesthesie is de anesthesioloog nog 
onkundig van de individuele dosis-respons relatie voor de betreffende patiënt, 
en is titreren dus niet mogelijk. Dit verklaart het belang van populatie PK-PD 
gegevens voor de inductie van anesthesie. Aangezien van veel 
geneesmiddelen niet bekend is wat de invloed is van verschillende variabelen 
op de inductie dosis-respons relatie, gaat de inductie van anesthesie bij veel 
patiënten gepaard met ernstige bijwerkingen, hoofdzakelijk hemodynamische 
instabiliteit. 
 
In dit proefschrift wordt de farmacologie van de inductie van anesthesie nader 
belicht. Vroege-fase kinetiek is complex en veelal afhankelijk van de 
bloedstroomsnelheid. De bevindingen in dit proefschrift tonen aan dat tijdens 
het modelleren van de dosis-concentratie-effect relatie de vroege fase 
gebrekkig beschreven wordt door compartimentele modellen. De toepassing 
van een recirculatoir PK-PD model leidt tot een grote verbetering hierin. De 
(niet)invasieve meting van ICG is onontbeerlijk bij recirculatoir modelleren. 
Deze meting van ICG is minder geschikt voor hemodynamische bewaking in de 
klinische praktijk. 
 
Bij aanvang van dit project gingen we uit van de hypothese dat het mogelijk 
zou moeten zijn om, aan het bed van de patiënt, op basis van een niet-
invasieve ICG meting, de relevante factoren van invloed voor de individuele 
patiënt te kunnen bepalen. De bepaling van het hartminuutvolume zou, op 
gelijke wijze, hier deel van uitmaken. Op basis van deze factoren zou het dan 
mogelijk zijn, met behulp van een recirculatoir model, een adequate en veilige 
inductie te bewerkstelligen met een anestheticum naar keuze. Deze 
doelstellingen zijn nog niet bereikt en vragen verder onderzoek. Toekomstig 




onderzoek zou zich moeten richten op het verhelderen van de invloed van 
verschillende covariaten op het recirculatoire model. Tevens zou gekeken 
moeten worden naar de relatie tussen de hoge piekconcentraties die gemeten 
worden na een bolus toediening en de hemodynamische depressie die 
optreedt tijdens inductie. Een ander onderwerp voor verder onderzoek is de 
invloed van comedicatie, zoals premedicatie in de vorm van opiaten of 
benzodiazepines, op de dosis-concentratie-effect relatie van propofol tijdens de 
inductiefase. Overigens zou het includeren in het onderzoek van 
patiëntengroepen met een andere fysiologie op basis van leeftijd, gewicht of 
bijkomende ziekte, ook meer informatie geven over de toepasbaarheid van het 
recirculatoire model in deze populaties. Daarnaast blijft de noodzaak bestaan 
tot het ontwikkelen van een snel reagerende en beter voorspellende 
meetwaarde van het anesthetische effect op het brein, in snel wisselende fases 
van het bewustzijn. Door het met hoge frequentie meten van geneesmiddelen 
concentraties en effect kunnen nog andere fenomenen onthuld worden, welke 
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